Persona
NORATA GIUSEPPE DANILO
PROFESSORE ORDINARIO
Settori (4)
Parole Chiave (3)
ATEROSCLEROSI
HDL
LIPOPROTEINE
No Results Found
Ricerca Finanziata (20)
Adoptive cell transfer of metabolic reprogrammed T regulatory cells to control atherosclerosis progression and to prevent end organ damage in cardiovascular disease.
PRIN2022 - PRIN bando 2022
Progetto
Responsabile scientifico
2023
24 mesi
Autoanticorpi anti-lipoproteine modificate in varie patologie cardiovascolari
PUR20062008 - PUR 2006-2008
Progetto
Partecipante
2006
Engineered T regulatory cells to control the immune-inflammatory response and the accelerated onset of atherosclerosis in familial hypercholesterolemia
FON_NAZ - Bandi Altre Fondazioni
Progetto
Responsabile scientifico
2013
36 mesi
Exploiting regulatory T-cell metabolic reprogramming and vascular tropism for Familial Hypercholesterolaemia immunotherapy
FON_NAZ - Bandi Altre Fondazioni
Progetto
Responsabile scientifico
2020
36 mesi
HDL quality vs quantity in coronary artery disease (HDL)
INTLI - Finanziamenti internazionali
Progetto
Responsabile scientifico
2017
24 mesi
Improving diagnosis and therapy for familial dyslipidaemias: a network of general practitioners and specialised lipid centers
MIS - Bandi Ministero Salute
Progetto
Responsabile scientifico
2021
36 mesi
Integrating metabolism and immunity: cellular and molecular pathways leading to metabolic dysregulation and autoimmunity
PRIN2017 - PRIN bando 2017
Progetto
Responsabile scientifico
2019
36 mesi
Investigating the neuro-immune-metabolic interfaces in human and experimental atherosclerosis
Progetti PNRR - Bandi competitivi da altri ministeri
Progetto
Responsabile scientifico
2023
24 mesi
Metabolic rewiring of diabetic heart: unveiling the role of lipoproteins on cardiac function
INTLI - Finanziamenti internazionali
Progetto
Responsabile scientifico
2019
18 mesi
Nanoparticles in Environment and Medical Research
Altri programmi di formazione internazionali o europei
Progetto
Responsabile scientifico
2023
30 mesi
National Center for Gene Therapy and Drugs based on RNA Technology
Progetti PNRR - per il potenziamento di strutture di ricerca e creazioni di campioni nazionali di R&S
Progetto
Responsabile scientifico
2022
36 mesi
PCSK9 and cardiac function: bridging cellular lipid metabolism to mitochondrial function and heart failure (PCSK9)
INTLI - Finanziamenti internazionali
Progetto
Responsabile scientifico
2018
24 mesi
2009-09-12 17:22:55.618
Proprotein convertase subtilisin/kexin type 9 (PCSK9): a link between lipotoxicity, mitochondrial dysfunction, and frailty-associated heart failure
CAR_RIC - Bandi Fondazione Cariplo
Progetto
Responsabile scientifico
2017
38 mesi
Role of microRNAs 143 and 145 in cardiovascular physiology and disease: from bench to bedside
CAR_RIC - Bandi Fondazione Cariplo
Progetto
Responsabile scientifico
2011
24 mesi
Ruolo di PCSK9 nella risposta postprandiale: basi molecolari e genetiche
ASS_NAZ - Bandi da Associazioni e altri Finanziatori privati nazionali
Progetto
Responsabile scientifico
2016
36 mesi
Tergeting inflammation in atherosclerosis: role and therapeutic potential of sphingosine 1-phosphate (S1P) and its receptors
MIS - Bandi Ministero Salute
Progetto
Responsabile scientifico
2014
36 mesi
Unveiling the impact of ASGR1 deficiency on the immunoinflammatory signature during atherogenesis (ASGR1 )
INTLI - Finanziamenti internazionali
Progetto
Responsabile scientifico
2018
34 mesi
Unveiling the impact of hepatic OPA1 deletion and Mitochondria-ER-Peroxisome interaction on bile acid synthesis and atherosclerosis development
INTLI - Finanziamenti internazionali
Progetto
Responsabile scientifico
2024
36 mesi
Unveiling the role of PCSK9 in heart physiology: focus on fatty acid metabolism, mitochondrial function and lipotoxicity.
INTLI - Finanziamenti internazionali
Progetto
Responsabile scientifico
2017
36 mesi
No Results Found
Pubblicazioni (249)
Comitati Editoriali (2)
Membro del Comitato Editoriale - CARDIOVASCULAR RESEARCH - ISSN: 0008-6363 - editore attuale:
ELSEVIER SCIENCE BV, PO BOX 211, AMSTERDAM, NETHERLANDS, 1000 AE
primo editore:
BMJ / British Medical Journal Publishing Group:PO Box 299, London WC1H 9TD United Kingdom:011 44 20 73836270, EMAIL: subscriptions@bmjgroup.com, INTERNET: http://www.bmjpg.com/bmj, Fax: 011 44 20 73836402 (2018 - 2024)
2018
Membro del Comitato Editoriale - ATHEROSCLEROSIS - ISSN: 0021-9150 - Tokyo; Oxford; New York; Lausanne; Shannon; Amsterdam: Elsevier (2017 - 2022)
2017
No Results Found
Ricerca E Didattica Presso Enti (2)
Incarico svolto presso: Curtin University
(01/01/2016 - 31/12/2018)20160101
Honorary Senior Lecturer presso: Queen Mary University of London
(01/04/2012 - 31/03/2017)20120401
No Results Found
Collegi Di Dottorato (13)
Università degli Studi di MILANO -
SCIENZE FARMACOLOGICHE BIOMOLECOLARI, SPERIMENTALI E CLINICHE-2023
(ciclo: 39 - Anno: 2023
2023
)
(COORDINATORE)
Università degli Studi di MILANO -
SCIENZE FARMACOLOGICHE BIOMOLECOLARI, SPERIMENTALI E CLINICHE-2022
(ciclo: 38 - Anno: 2022
2022
)
(COORDINATORE)
Università degli Studi di MILANO -
SCIENZE FARMACOLOGICHE BIOMOLECOLARI, SPERIMENTALI E CLINICHE-2021
(ciclo: 37 - Anno: 2021
2021
)
(COORDINATORE)
Università degli Studi di MILANO -
SCIENZE FARMACOLOGICHE BIOMOLECOLARI, SPERIMENTALI E CLINICHE-2020
(ciclo: 36 - Anno: 2020
2020
)
Università degli Studi di MILANO -
SCIENZE FARMACOLOGICHE BIOMOLECOLARI, SPERIMENTALI E CLINICHE-2019
(ciclo: 35 - Anno: 2019
2019
)
Università degli Studi di MILANO -
SCIENZE FARMACOLOGICHE BIOMOLECOLARI, SPERIMENTALI E CLINICHE-2018
(ciclo: 34 - Anno: 2018
2018
)
Università degli Studi di MILANO -
SCIENZE FARMACOLOGICHE SPERIMENTALI E CLINICHE-2017
(ciclo: 33 - Anno: 2017
2017
)
Università degli Studi di MILANO -
SCIENZE FARMACOLOGICHE SPERIMENTALI E CLINICHE-2016
(ciclo: 32 - Anno: 2016
2016
)
Università degli Studi di MILANO -
SCIENZE FARMACOLOGICHE SPERIMENTALI E CLINICHE-2015
(ciclo: 31 - Anno: 2015
2015
)
Università degli Studi di MILANO -
SCIENZE FARMACOLOGICHE SPERIMENTALI E CLINICHE-2014
(ciclo: 30 - Anno: 2014
2014
)
Università degli Studi di MILANO -
SCIENZE FARMACOLOGICHE SPERIMENTALI E CLINICHE-2013
(ciclo: 29 - Anno: 2013
2013
)
Università degli Studi di MILANO -
SCIENZE FARMACOLOGICHE-2012
(ciclo: 28 - Anno: 2012
2012
)
Università degli Studi di MILANO -
SCIENZE FARMACOLOGICHE-2011
(ciclo: 27 - Anno: 2011
2011
)
No Results Found
Tutoraggio (13)
tutorship -
Dottorandi
- RODA SILVIA
(30/01/2023 - )
20230130
tutorship -
Dottorandi
- VINGIANI GIOVANNI BATTISTA
(19/01/2023 - )
20230119
tutorship -
Dottorandi
- MANNELLA FRANCESCA CAROLINA
(05/10/2022 - )
20221005
tutorship -
Dottorandi
- FANTINI FRANCESCA
(01/10/2022 - )
20221001
tutorship -
Dottorandi
- TERENGHI OTTAVIA
(01/10/2022 - )
20221001
tutorship -
Dottorandi
- DE MICCO MASSIMILIANO
(01/10/2021 - 18/09/2023)
20211001
tutorship -
Dottorandi
- BELLINI ROSSELLA
(01/11/2020 - 18/01/2024)
20201101
tutorship -
Dottorandi
- NOUR JASMINE
(01/11/2020 - 18/01/2024)
20201101
tutorship -
Dottorandi
- SVECLA MONIKA
(01/10/2019 - 04/04/2023)
20191001
tutorship -
Dottorandi
- DA DALT LORENZO
(01/10/2017 - 16/02/2021)
20171001
tutorship -
Dottorandi
- MOREGOLA ANNALISA
(01/10/2015 - 17/12/2018)
20151001
tutorship -
Dottorandi
- BONACINA FABRIZIA
(01/11/2012 - 12/01/2016)
20121101
tutorship -
Assegnisti
- BARAGETTI ANDREA
(01/04/2012 - 31/03/2013)
20120401
No Results Found
Public Engagement
Organizzazione di iniziative di valorizzazione, consultazione e condivisione della ricerca (Discussant)
- IV Giornata della Ricerca del Centro E. Grossi Paoletti "La prevenzione cardiovascolare nell’era post-COVID"
19000101
Dipartimento di Scienze Farmaceutiche
Dipartimento di Scienze Farmacologiche e Biomolecolari
Dipartimento di Oncologia ed Emato-Oncologia
No Results Found
Description
INFORMAZIONI PERSONALI Giuseppe Danilo Norata
ESPERIENZA PROFESSIONALE
Dal 2018 ad oggi Professore Ordinario di Farmacologia
Dipartimento di Scienze Farmacologiche e Biomolecolari, Facoltà di Scienze del Farmaco, Via Balzaretti 9, Milano, www.unimi.it
Insegnamenti collegatati al settore disciplinare 05/G1 Farmacologia BIO-14 nei corsi si Laurea di Farmacia e Biotecnologie del Farmaco, Facoltà di scienze del Farmaco e nel corso di Laurea di Scienze Biologiche, Facoltà di Scienze e Tecnologie
Dal 2016 al 2018 Adjunct Professor
School of Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia
Dal 2014 al 2018 Professore Associato di Farmacologia
Dipartimento di Scienze Farmacologiche e Biomolecolari, Facoltà di Scienze del Farmaco, Via Balzaretti 9, Milano, www.unimi.it
▪ Insegnamento di discipline correlate alla Farmacologia e Tossicologia agli studenti dei Corsi di Laurea delle Facoltà di Scienze del Farmaco e Scienze Biologiche
Settore disciplinare 05/G1 Farmacologia BIO-14
Dal 2012 al 2015 Honorary Senior Lecturer
The Blizard Institute, Barts and The London, School of Medicine & Dentistry Queen Mary University, Londra, Regno Unito
Dal 2008 al 2014 Ricercatore Universitario
Dipartimento di Scienze Farmacologiche e Biomolecolari, Facoltà di Scienze del Farmaco, Via Balzaretti 9, Milano, www.unimi.it
▪ Insegnamento di discipline correlate alla Farmacologia agli studenti dei Corsi di Laurea della Facoltà di Scienze del Farmaco
Settore disciplinare 05/G1 Farmacologia BIO-14
Dal 2002 al 2008 Assegnista di Ricerca
Dipartimento di Scienze Farmacologiche e Biomolecolari, Facoltà di Farmacia, Via Balzaretti 9, Milano, www.unimi.it
▪ Ricerca di base ed applicata in campo cardiovascolare
ISTRUZIONE E FORMAZIONE
Dal 2005 a oggi Responsabile del Laboratorio di Genetica Molecolare e Genomica Cardiovascolare
Centro per lo Studio dell’Aterosclerosi, Ospedale E. Bassini, Cinisello Balsamo, Milano
▪ Organizzazione pianificazione della ricerca in ambito cardiovascolare
Dal 2002 al 2004 Visiting Scientist
Atherosclerosis Research Unit, Karolinska Hospital, Karolinska Institute, Stoccolma, Svezia
▪ Ricerca in campo genetico e di genomica cardiovascolare
2003 Laurea in Biotecnologie Farmaceutiche (Seconda Laurea) Votazione 110/110 e lode
Dipartimento di Scienze Farmacologiche, Facoltà di Farmacia, via Balzaretti 9, Milano
Università degli Studi di Milano
▪ Biotecnologie Applicate alla Ricerca Biomedica
2002 Scuola di Specialità in Farmacologia
Votazione 70/70 e lode
Dipartimento di Scienze Farmacologiche, Facoltà di Farmacia, via Balzaretti 9, Milano
Università degli Studi di Milano
▪ Ricerca di base ed applicata in campo cardiovascolare
Dal 1998 al 2001 Dottorato di Ricerca (PhD)
Medicina Sperimentale: Aterosclerosi
Università degli Studi di Siena
1996 Laurea in Farmacia
Votazione 110/110 e lode
Dipartimento di Scienze Farmacologiche, Facoltà di Farmacia, via Balzaretti 9, Milano
Università degli Studi di Milano
▪ Discipline Farmaceutiche
COMPETENZE PERSONALI
Lingua madre Italiano
Altre lingue COMPRENSIONE PARLATO PRODUZIONE SCRITTA
Ascolto Lettura Interazione Produzione orale
Inglese C1 C1 C1 C1 C1
Competenze organizzative e gestionali ▪ Leadership (attualmente responsabile di un team di 10 persone)
ATTIVITA’ PROFESSIONALI
Progetti e Finanziamenti
2019-2022 PRIN: PROGETTI DI RICERCA DI RILEVANTE INTERESSE NAZIONALE
Bando 2017 (Prot. 2017K55HLC)
“Integrating metabolism and immunity: cellular and molecular pathways leading to metabolic dysregulation and autoimmunity”
Coordinatore di Unità
2019-2022 Fondazione Telethon GGP19146
“Exploiting regulatory T-cell metabolic reprogramming and vascular tropism as therapeutic tools for Familial Hypercholesterolemia”
Coordinatore del Progetto
2019-2020 EFSD/Lilly European Diabetes Research Programme; Bando Internazionale
“Metabolic rewiring of diabetic heart: unveiling the role of lipoproteins on cardiac function”
Coordinatore del Progetto
2018-2020 PCSK9 Competitive Grant Program, Amgen
“PCSK9 and cardiac function: bridging cellular lipid metabolism to mithocondrial function and heart failure”
Coordinatore del Progetto
2018-2020 ASGR1 Cardiovascular Grant, 3268293 Amgen; Bando Internazionale
“Unveiling the impact of ASGR1 deficiency on the immunoinflammatory signature during atherogenesis”
Coordinatore del Progetto
2017-2020 Fondazione Cariplo, Bando Ricerca Scientifica, 2016-0852, Bando Nazionale
“Proprotein convertase subtilisin/kexin type 9 (PCSK9): a link between lipotoxicity, mitochondrial dysfunction, and frailty-associated heart failure”
Coordinatore del Progetto
2017-2020 Aspire Cardiovascular Grant, WI218287, Bando Internazionale
“Unveiling the role of PCSK9 in heart physiology: focus on fatty acid metabolism, mitochondrial function and lipotoxicity”
Coordinatore del Progetto
2016-2020 Società Italiana Terapia Clinica e Sperimentale, STCS15-Mi-02, Bando Nazionale
“Role of PCSK9 in the post-prandial response: genetic and molecular aspects”
Coordinatore del Progetto
2017-2019 Fondazione Italiana per il Tuo Cuore, Centro Studi ANMCO, 470/15/HCF, Bando Nazionale
“HDL quality vs quantity in coronary artery disease”
Coordinatore del Progetto
2014-2018 Ministero della Salute, Bando Ricerca Finalizzata 2011-12, WFR GR-2011-02346974, Bando Nazionale
“Targeting inflammation in atherosclerosis: role and therapeutic potential of sphingosine 1-phosphate (S1P) and its receptors”
Responsabile di Unità
2013-2017 Fondazione Telethon GGP13002, Bando Nazionale
“Engineered T regulatory cells to control the immune-inflammatory response and the accelerated onset of atherosclerosis in familial hypercholesterolemia”
Coordinatore del Progetto
2012-2014 EU, COST Action BM0904_HDLnet, Bando Internazionale
“HDL: From Biological Understanding to Clinical Exploitation”
Responsabile di Unità
2011-2013 Fondazione Cariplo, Bando Ricerca Scientifica, 2010-0768, Bando Nazionale
“Role of Micro RNAs 143 and 145 in cardiovascular physiology and disease: from bench to bedside”
Responsabile di Unità
Competenze professionali Revisore per le seguenti Riviste Scientifiche
Acta Biochimica et Biophysica Sinica
Acta Diabetologica
Aging Health
American Journal of Pathology
American Journal of Physiology: Endocrinology and Metabolism
American Journal of Human Biology
Annals of Medicine
Arteriosclerosis Thrombosis Vascular Biology
Atherosclerosis
Biochemical Pharmacology
Biochimica et Byophisica Acta
Biomarkers
British Journal of Haematology
Cardiovascular Research
Cell Proliferation
Clinica Chimica Acta
Clinical Chemistry and Laboratory Medicine
Clinical Journal of American Society of Nephrology
Clinical Endocrinology
Clinical and Experimental Medicine
Clinical Nutrition
Cytokine
Diabetes Research and Clinical Practice
Diabetologia
Expert Review of Cardiovascular Therapy
European Heart Journal
European Heart Journal Preventive Cardiology
European Journal of Endocrinology
European Journal of Lipid Science and Technology
European Journal of Pharmacology
FEBS letter
Future Cardiology
Heart and Vessels
Hypertension
Human Immunology
International Journal of Obesity
Journal of Atherosclerosis and Thrombosis
Journal of the American College of Nutrition
Journal of Biological Regulators
Journal of Diabetes and Its Complications
Journal of Endocrinology
Journal of Internal Medicine
Journal of Leukocyte Biology
La Caixa
Life Sciences
Maturitas
Mediators of Inflammation
Medical Science Monitoring
Metabolism
Nutrition Metabolism and Cardiovascular Disease
Obesity
Pharmaceutical Biology
Pharmacological Research
Stroke
Thrombosis and Haemostasis
The Scandinavian Journal of Clinical & Laboratory Investigation
The Scandinavian Journal of Rheumatology
Tohoku Journal of Experimental Medicine
Toxicology Letters
Vascular Health and Risk Management
Associate Editor per le seguenti Riviste Scientifiche:
Annals of Medicine
Atherosclerosis
Cardiovascular Research
Giornale Italiano dell'Arteriosclerosi
Nutrition Metabolism and Cardiovascular Diseases
Public Library of Science (PLoS) One
Cariche Professionali e Accademiche ▪ Coordinatore del corso di dottorato di ricerca in Scienze farmacologiche biomolecolari, sperimentali e cliniche, 2020-2023.
▪ Vice Presidente SISA Lombardia, ad oggi.
▪ Section Editor della Rivista Scientifica Annals of Medicine
▪ Membro Advisory Board del National Institute of Rheumatic
▪ Tesoriere del gruppo ATVB dell’ESC “European Society of Cardiology”
▪ Delegato tavolo di Lavoro Patologie Diabetiche della Federazione Italiana Scienze Mediche (FISM), rappresentane della Società Italiana di Farmacologia 2019 ad oggi.
▪ Componente ESC Working Group on Atherosclerosis & Vascular Biology, Società Europea di Cardiologia (ESC). 2018 ad oggi.
▪ Membro del Comitato scientifico del Congresso Nazionale SIF 2020-2022
▪ Membro della Società Italiana di Farmacologia (SIF)-farmaindustria, ad oggi.
▪ Componente del Scientific Programme Committee e del Congress Committee, Società Europea per lo Studio dell’Aterosclerosi (EAS)
▪ Comitato Coordinatore “Giovani SISA” (fino al 2016), membro del Direttivo SISA Lombardia (dal 2015), Società Italiana per lo Studio dell’Aterosclerosi (SISA).
▪ Membro dell’ Associazione Europea per lo Studio del Diabete (EASD)
▪ Membro del Comitato Organizzatore e Scientifico dei seguenti Congressi:
• 89th Congress of the European Atherosclerosis Society, Helsinki 2021.
• 88th Congress of the European Atherosclerosis Society, Geneva 2020.
• 87th Congress of the European Atherosclerosis Society, Maastricht 2019.
• 86th Congress of the European Atherosclerosis Society, Lisbona 2018.
• 85th European Atherosclerosis Society meeting, Prague 2017. Scientific Committee
• 39th European Lipoprotein Club Meeting, Tutzing, Germany 2016.
• 84th European Atherosclerosis Society meeting, Innsbruck 2016. Congress Committee
• 83rd European Atherosclerosis Society meeting, Glasgow 2015. Poster Coordinator and Young Investigators chairs.
• 38th European Lipoprotein Club Meeting, Tutzing, Germany 2015.
• 82nd European Atherosclerosis Society meeting, Madrid 2014. Poster Coordinator.
• 37th European Lipoprotein Club Meeting, Tutzing, Germany 2014.
• 81st European Atherosclerosis Society meeting, Lyon 2013. Poster Award Committee.
• 36th European Lipoprotein Club Meeting, Tutzing, Germany 2013
• 80th European Atherosclerosis Society meeting, Milan 2012.
• 35th European Lipoprotein Club Meeting, Tutzing, Germany 2012
• XV International Symposium on Drugs Affecting Lipid Metabolism. Venice 2004
• Second International Meeting on PPARs: from Basic Science to Clinical Applications, Florence 2003
• 6th International Meeting on global risk assessment in cardiovascular disease and stroke. Florence 2002
• First International Meeting on PPARs: from Basic Science to Clinical Applications. Florence 2001
▪ Revisore di Richieste di Finanziamento per le seguenti Istituzioni di Ricerca:
• Dutch Research Council NWO
• Netherlands, Canada
• Dutch Heart Foundation, The Netherlands
• ERC Starting Grant, Brussels
• FWF Austrian Science Fund, Austria
• Medical Research Council, Regno Unito
• Ministero Italiano dell’Università e della Ricerca (MIUR), Italia
• Agence Nationale de la Recherche, Francia
• Dutch Diabetes Research Foundation, Paesi Bassi
• South African Medical Research Council, Sud Africa
• Conacuore Onlus, PRICARD grants, Italia
• Research Foundation Flanders (FWO), Belgio
• European Project RBUCE-UP, Francia
• Diabetes UK, Regno Unito
▪ Membro della Commissione Giudicatrice Esame finale Dottorato di Ricerca in Scienze del Farmaco, Università di Parma.
▪ Componente della Commissione Programma Erasmus Università degli Studi di Milano
▪ Componente della Commissione Paritetica del Corso di Laurea di Biotecnologie del Farmaco. Facoltà di Scienze del Farmaco.
▪ Componente di Commissioni per il conferimento di Borse Giovani Promettenti e per il conferimento ed il rinnovo di Assegni di Ricerca per il Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano.
▪ Componente della Commissione di vigilanza degli Esami di Stato per l’abilitazione all’esercizio della Professione di Farmacista.
▪ Componente del Collegio dei Docenti del Dottorato di Ricerca in Scienze Farmacologiche Sperimentali e Cliniche, Università degli Studi di Milano.
▪ Valutatore delle tesi di Dottorato dell’Università degli Studi di Roma la Sapienza.
▪ Componente del Comitato Etico (Farmacologo) degli Istituti Clinici di Perfezionamento.
ULTERIORI INFORMAZIONI
Pubblicazioni
Totale
Public. Public. con IF IF totale IF medio Total citaz Scopus H-index
208
173
1168,311 6,753 7165 48
1. Genetically determined hypercholesterolaemia results into premature leucocyte telomere length shortening and reduced haematopoietic precursors. Baragetti A, Bonacina F, Da Dalt L, Moregola A, Zampoleri V, Pellegatta F, Grigore L, Pirillo A, Spina R, Cefalù AB, Averna M, Norata GD , Catapano AL. Eur J Prev Cardiol. 2020 Nov 17:zwaa115. doi: 10.1093/eurjpc/zwaa115. Online ahead of print.PMID: 33624064
IF 5.864
2. Novel acquisitions in cell immunometabolism. Norata GD , Matarese G.
Mol Aspects Med. 2021 Feb;77:100945. doi: 10.1016/j.mam.2021.100945. Epub 2021 Feb 5.PMID: 33551237 IF 9.577
3. Gut microbiota functional dysbiosis relates to individual diet in subclinical carotid atherosclerosis. Baragetti, A., Severgnini, M., Olmastroni, E., ... Norata GD , Catapano, A.L., Peano, C. Nutrients, 2021 Jan 21;13(2):304. doi: 10.3390/nu13020304. PMID: 33494335 IF 4.546
4. Worldwide Changes in Total Cholesterol and Non-HDL-Cholesterol Trends Indicate Where the Challenges Are for the Coming Years. Pirillo A, Norata GD, Catapano AL. Clin Chem. 2021 Jan 8;67(1):30-32. doi: 10.1093/clinchem/hvaa246.PMID: 33236047
IF 7.292
5. Insights from ORION studies: focus on inclisiran safety. Catapano AL, Pirillo A, Norata GD. Cardiovasc Res. 2021 Jan 1;117(1):24-26. doi: 10.1093/cvr/cvaa139. IF 8.168
6. Endothelial Function in cardiovascular prevision medicine: a position paper on behalf of the European Society of Cardiology. Alexander Y, Osto E, Schmidt-Trucksäss A, Shechter M, Trifunovic D, Duncker DJ, Aboyans V, Bäck M, Badimon L, Cosentino F, De Carlo M, Dorobantu M, Harrison DG, Guzik TJ, Hoefer I, Morris PD, Norata GD, Suades R, Taddei S, Vilahur G, Waltenberger J, Weber C, Wilkinson F, Bochaton-Piallat ML, Evans PC. Cardiovasc Res. 2021 Jan 1;117(1):29-42. doi: 10.1093/cvr/cvaa085. IF 8.168
7. Low Plasma Lecithin: Cholesterol Acyltransferase (LCAT) Concentration Predicts Chronic Kidney Disease. Baragetti A, Ossoli A, Strazzella A, Simonelli S, Baragetti I, Grigore L, Pellegatta F, Catapano AL, Norata GD, Calabresi L.J Clin Med. 2020 Jul 18;9(7):2289. doi: 10.3390/jcm9072289.PMID: 32708515 IF 1.883
8. Caloric Restriction Promotes Immunometabolic Reprogramming Leading to Protection from Tuberculosis. Palma C, La Rocca C, Gigantino V, Aquino G, Piccaro G, Di Silvestre D, Brambilla F, Rossi R, Bonacina F, Lepore MT, Audano M, Mitro N, Botti G, Bruzzaniti S, Fusco C, Procaccini C, De Rosa V, Galgani M, Alviggi C, Puca A, Grassi F, Rezzonico-Jost T, Norata GD, Mauri P, Netea MG, de Candia P, Matarese G. Cell Metab. 2021 Jan 4:S1550-4131(20)30671-9. doi: 10.1016/j.cmet.2020.12.016. Cell Metabolism, 2021 Feb 2;33(2):300-318.e12. doi: 10.1016/j.cmet.2020.12.016.
Epub 2021 Jan 8. PMID: 33421383 IF 21.567
9. Adoptive transfer of CX3CR1 transduced-T regulatory cells improves homing to the atherosclerotic plaques and dampens atherosclerosis progression. Bonacina F, Martini E, Svecla M, Nour J, Cremonesi M, Beretta G, Moregola A, Pellegatta F, Zampoleri V, Catapano AL, Kallikourdis M, Norata GD. Cardiovasc Res. 2020 Sep 15:cvaa264. doi: 10.1093/cvr/cvaa264. Online ahead of print.PMID: 32931583 IF 8.168
10. Metabolic adaptations of cells at the vascular-immune interface during atherosclerosis.
Bonacina F, Da Dalt L, Catapano AL, Norata GD. Mol Aspects Med. 2020 Oct 5:100918. doi: 10.1016/j.mam.2020.100918. Online ahead of print.PMID: 33032828
IF 9.577
11. Dyslipidemia and regulatory T cell migration: an immunometabolic connection?
Binder C, Norata GD. Cardiovasc Res. 2020 Sep 17:cvaa269. doi: 10.1093/cvr/cvaa269. Online ahead of print.PMID: 32941603 IF 8.168
12. Omega n-3 Supplementation: Exploring the Cardiovascular Benefits Beyond Lipoprotein Reduction. Zambon A, Pirillo A, Zambon S, Norata GD, Catapano AL. Curr Atheroscler Rep. 2020 Oct 3;22(12):74. doi: 10.1007/s11883-020-00893-1.PMID: 33009961 IF 4.608
11. Recent insights into low-density lipoprotein metabolism and therapy. Angela Pirillo, Alberico Catapano, and Norata GD. Curr Opin Clin Nutr Metab Care. 2021 Mar 1;24(2):120-126. doi: 10.1097/MCO.0000000000000727.PMID: 33394716 IF 3.775
13. Epidemiology of dyslipidaemias Angela Pirillo, Manuela Casula, Elena Olmastroni, Norata GD, and Alberico Catapano. Nature Reviews Cardiology. 2020 [Epub ahead of print] IF 20.260
14. Impact of protein glycosylation on lipoprotein metabolism and atheroslcerosis. Norata GD Cardiovasc Res.[Epub ahead of print] IF 8.168
15. P2X7 receptor activity limits accumulation of T cells within tumors.
Fabio Grassi, Andrea Romagnani, Elsa Rottoli, Emilia Maria Cristina Mazza, Tanja Rezzonico-Jost, Benedetta De Ponte Conti, Michele Proietti, Michela Perotti, Elisa Civanelli, Lisa Perruzza, Alberico L. Catapano, Andrea Baragetti, Elena Tenedini, Enrico Tagliafico, Simonetta Falzoni, Francesco Di Virgilio, Norata GD , and Silvio Bicciato. Cancer Research 2020 Jul 22;canres.3807.2019. doi: 10.1158/0008-5472.CAN-19-3807. Online ahead of print. IF 9.727
16. New pharmacological approaches to target PCSK9. Catapano AL, Pirillo A, Norata GD. Current Atherosclerosis Reports. 2020 Jun 3;22(7):24. doi: 10.1007/s11883-020-00847-7 IF 4.608
17. LDL-Cholesterol-Lowering Therapy. Pirillo A, Norata GD, Catapano AL.
Handb Exp Pharmacol. 2020 Apr 30. doi: 10.1007/164_2020_361
18. Efficacy and Safety of Volanesorsen (ISIS 304801): the Evidence from Phase 2 and 3 Clinical Trials. Fogacci F, Norata GD, Peter P. Toth, Arca M., Cicero A.F. G
Current Atherosclerosis Reports doi: 10.1007/s11883-020-00836-w IF 4.608
19. Beyond LDL-C levels, does remnant cholesterol estimation matter? Pirillo A, Norata GD, Catapano AL.
Eur J Prev Cardiol. 2020 Feb 3:2047487319899622. doi: 10.1177/2047487319899622. [Epub ahead of print]. IF 5.864
20. Progression of conventional cardiovascular risk factors and vascular disease risk in individuals: insights from the PROG-IMT consortium. Bahls M, Lorenz MW, Dörr M, Gao L, Kitagawa K, Tuomainen TP, Agewall S, Berenson G, Catapano AL, Norata GD, Bots ML, van Gilst W, Asselbergs FW, Brouwers FP, Uthoff H, Sander D, Poppert H, Hecht Olsen M, Empana JP, Schminke U, Baldassarre D, Veglia F, Franco OH, Kavousi M, de Groot E, Mathiesen EB, Grigore L, Polak JF, Rundek T, Stehouwer CD, Skilton MR, Hatzitolios AI, Savopoulos C, Ntaios G, Plichart M, McLachlan S, Lind L, Willeit P, Steinmetz H, Desvarieux M, Ikram MA, Johnsen SH, Schmidt C, Willeit J, Ducimetiere P, Price JF, Bergström G, Kauhanen J, Kiechl S, Sitzer M, Bickel H, Sacco RL, Hofman A, Völzke H, Thompson SG; PROG-IMT Study Group. Eur J Prev Cardiol. 2019 Oct 16:2047487319877078. doi: 10.1177/2047487319877078 IF 5.864
21. Cholesterol membrane content has a ubiquitous evolutionary function in immune cell activation: the role of HDL. Bonacina F, Pirillo A, Catapano AL, Norata GD. Curr Opin Lipidol. 2019 Oct ;30(6):462-469. IF 4.254
22. Lipid accumulation impairs lysosomal acid lipase activity in hepatocytes: Evidence in NAFLD patients and cell cultures. Gomaraschi M, Fracanzani AL, Dongiovanni P, Pavanello C, Giorgio E, Da Dalt L, Norata GD, Calabresi L, Consonni D, Lombardi R, Branchi A, Fargion S. Biochim Biophys Acta Mol Cell Biol Lipids. 2019 Sep 7;1864(12):158523. IF 4.519
23. Acido Bempedoico: dalla Farmacologia alla Clinica. Pirillo A, Catapano AL, Norata GD. Giornale Italiano dell’Arteriosclerosi. 2019;10(3):40-49.
24. Hormonal control of trained immunity: aldosterone at the crossroad between activation of innate immunity and cardiovascular diseases. Matarese G, Norata GD. Cardiovasc Res. 2019 2020 Feb 1;116(2):256-257. IF 8.168
25. Single systemic transfer of a human gene associated with exceptional longevity halts the progression of atherosclerosis and inflammation in ApoE knockout mice through a CXCR4-mediated mechanism. Puca AA, Carrizzo A, Spinelli C, Damato A, Ambrosio M, Villa F, Ferrario A, Maciag A, Fornai F, Lenzi P, Valenti V, di Nonno F, Accarino G, Madonna M, Forte M, Calì G, Baragetti A, Norata GD, Catapano AL, Cattaneo M, Izzo R, Trimarco V, Montella F, Versaci F, Auricchio A, Frati G, Sciarretta S, Madeddu P, Ciaglia E, Vecchione C. Eur Heart J. 2019 Jul 10. pii: ehz459. doi: 10.1093/eurheartj/ehz459. IF 22.673
26. Fuel for thought: Immunometabolism is a paradigm shift in understanding immunity in cardiovascular disease. Caligiuri G, Norata GD. Cardiovasc Res. 2019;115(9):1383-1384. IF 8.168
27. Immunometabolic function of cholesterol in cardiovascular disease and beyond. Yvan-Charvet L, Bonacina F, Guinamard RR, Norata GD. Cardiovasc Res. 2019;115(9):1393-1407. IF 8.168
28. The role of monocytes and macrophages in human atherosclerosis, plaque neoangiogenesis and atherothrombosis. Moroni F, Ammirati E, Norata GD, Magnoni M, Camici PG. Mediators Inflamm. 2019:7434376. IF 3.758
29. Cholesterol metabolism, pancreatic β-cell function and diabetes. Perego C, Da Dalt L, Pirillo A, Galli A, Catapano AL, Norata GD. Biochim Biophys Acta Mol Basis Dis. 2019;1865(9):2149-2156. IF 4.519
30. Identification of AnnexinA1 as an endogenous regulator of RhoA, and its role in the pathophysiology and experimental therapy of type 2 diabetes. Purvis GSD, Collino M, Loiola RA, Baragetti A, Chiazza F, Brovelli M, Sheikh MH, Collotta D, Cento A, Mastrocola R, Aragno M, Cutrin JC, Reutelingsperger C, Grigore L, Catapano AL, Yaqoob MM, Norata GD, Solito E, Thiemermann C. Front Immunol. 2019;10:571.
IF 5.085
31. The Interconnection Between Immuno-Metabolism, Diabetes, and CKD. Bonacina F, Baragetti A, Catapano AL, Norata GD. Curr Diab Rep. 2019 Mar 19;19(5):21. IF 3.686
32. Pentraxin 3 deficiency protects from the metabolic inflammation associated to diet-induced obesity. Bonacina F, Moregola A, Porte R, Baragetti A, Bonavita E, Salatin A, Grigore L, Pellegatta F, Molgora M, Sironi M, Barbati E, Mantovani A, Bottazzi B, Catapano AL, Garlanda C, Norata GD. Cardiovasc Res. 2019 Nov 1;115(13):1861-1872.
IF 8.168
33. Lysosomal Acid Lipase: From Cellular Lipid Handler to Immunometabolic Target. Gomaraschi M, Bonacina F, Norata GD. Trends Pharmacol Sci. 2019;40(2):104-115.
IF 13.503
34. Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies. Seidah NG, Prat A, Pirillo A, Catapano AL, Norata GD. Cardiovasc Res. 2019 Mar 1;115(3):510-518. IF 8.168
35. Impact of Cardiovascular Risk Factors and Pharmacologic Treatments on Carotid Intraplaque Neovascularization Detected by Contrast-Enhanced Ultrasound. Magnoni M, Ammirati E, Moroni F, Norata GD, Camici PG. J Am Soc Echocardiogr. 2019;32(1):113-120. IF 5.508
36. High-density lipoprotein cholesterol levels, cardiovascular disease risk and cancer: a relation which does not apply to all? Catapano AL, Pirillo A, Norata GD. Cardiovasc Res. 2019;115(1):6-7. IF 8.168
37. Biological consequences of dysfunctional HDL. Pirillo A, Catapano AL, Norata GD. Curr Med Chem. 2019;26(9):1644-1664. IF 4.184
38. PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the LDL receptor. Da Dalt L, Ruscica M, Bonacina F, Balzarotti G, Dhyani A, Di Cairano E, Baragetti A, Arnaboldi L, De Metrio S, Pellegatta F, Grigore L, Botta M, Macchi C, Uboldi P, Perego C, Catapano AL, Norata GD. Eur Heart J. 2019; 40(4):357-368. IF 22.673
39. Applicazioni traslazionali dell'immunometabolismo nelle malattie metaboliche e nel diabete. Bonacina F, Baragetti A, Catapano AL, Norata GD. Il Diabete, 2018; 30(3):216-225.
40. Gene silencing strategies in the treatment of dyslipidemias. Pirillo A, Catapano AL, Norata GD. Giornale Italiano dell’Arteriosclerosi, 2018; 9(2):34-46.
41. Myeloid Apolipoprotein E controls Dendritic Cell antigen presentation function and adaptive immunity. Bonacina F, Coe D, Wang G, Longhi MP, Baragetti A, Moregola A, Garlaschelli K, Uboldi P, Pellegatta F, Grigore L, Da Dalt L, Annoni A, Gregori S, Xiao Q, Caruso D, Mitro N, Catapano AL, Marelli-Berg FM, Norata GD. Nat Commun. 2018; 9(1):3083. IF 11.878
42. Cluster-assembled zirconia substrates promote long term differentiation and functioning of human islets of Langerhans. Galli A, Maffioli E, Sogne E, Moretti S, di Cairano ES, Negri A, Nonnis S, Norata GD, Bonacina F, Borghi F, Podesta A, Bertuzzi F, Milani P, Lenardi C, Tedeschi G, Perego C. Sci Rep. 2018;8(1):9979.
IF 4.011
43. Fatty acid metabolism complements glycolysis in the selective regulatory T cell expansion during tumor growth. Pacella I, Procaccini C, Focaccetti C, Miacci S, Timperi E, Faicchia D, Severa M, Rizzo F, Coccia EM, Bonacina F, Mitro N, Norata GD, Rossetti G, Ranzani V, Pagani M, Giorda E, Wei Y, Matarese G, Barnaba V, Piconese S. Proc Natl Acad Sci. 2018;115(28):E6546-E6555. IF 9.580
44. Trained immunity and cardiovascular disease: is it time for translation to humans? Norata GD. Cardiovasc Res. 2018;114(6):e41-e42. IF 7.014
45. Proprotein Convertase Subtilisin-Kexin type-9 (PCSK9) and triglyceride-rich lipoprotein metabolism: Facts and gaps. Baragetti A, Grejtakova D, Casula M, Olmastroni E, Jotti GS, Norata GD, Catapano AL, Bellosta S. Pharmacol Res. 2018;130:1-11. IF 5.574
46. The Interplay of Lipids, Lipoproteins, and Immunity in Atherosclerosis. Pirillo A, Bonacina F, Norata GD, Catapano AL. Curr Atheroscler Rep. 2018;20(3):12. IF 3.769
47. Predictive value for cardiovascular events of common carotid intima media thickness and its rate of change in individuals at high cardiovascular risk - Results from the PROG-IMT collaboration. Lorenz MW, Gao L, Ziegelbauer K, Norata GD, Empana JP, Schmidtmann I, Lin HJ, McLachlan S, Bokemark L, Ronkainen K, Amato M, Schminke U, Srinivasan SR, Lind L, Okazaki S, Stehouwer CDA, Willeit P, Polak JF, Steinmetz H, Sander D, Poppert H, Desvarieux M, Ikram MA, Johnsen SH, Staub D, Sirtori CR, Iglseder B, Beloqui O, Engström G, Friera A, Rozza F, Xie W, Parraga G, Grigore L, Plichart M, Blankenberg S, Su TC, Schmidt C, Tuomainen TP, Veglia F, Völzke H, Nijpels G, Willeit J, Sacco RL, Franco OH, Uthoff H, Hedblad B, Suarez C, Izzo R, Zhao D, Wannarong T, Catapano A, Ducimetiere P, Espinola-Klein C, Chien KL, Price JF, Bergström G, Kauhanen J, Tremoli E, Dörr M, Berenson G, Kitagawa K, Dekker JM, Kiechl S, Sitzer M, Bickel H, Rundek T, Hofman A, Mathiesen EB, Castelnuovo S, Landecho MF, Rosvall M, Gabriel R, de Luca N, Liu J, Baldassarre D, Kavousi M, de Groot E, Bots ML, Yanez DN, Thompson SG; PROG-IMT study group. PLoS One 2018;13(4):e0191172. IF 2.776
48. Zc3h10 is a novel mitochondrial regulator. Audano M, Pedretti S, Cermenati G, Brioschi E, Diaferia G, Ghisletti S, Cuomo A, Bonaldi T, Salerno F, Mora M, Grigore L, Garlaschelli K, Baragetti A, Bonacina F, Catapano AL, Norata GD, Crestani M, Caruso D, Saez E, De Fabiani E, Mitro N. EMBO Rep. 2018;19(4). IF 8.383
49. Regulatory T Cell Migration Is Dependent on Glucokinase-Mediated Glycolysis. Kishore M, Cheung KCP, Fu H, Bonacina F, Wang G, Coe D, Ward EJ, Colamatteo A, Jangani M, Baragetti A, Matarese G, Smith DM, Haas R, Mauro C, Wraith DC, Okkenhaug K, Catapano AL, De Rosa V, Norata GD, Marelli-Berg FM. Immunity. 2017;47(5):875-889. IF 19.734
50. Disease trends over time and CD4+CCR5+ T-cells expansion predict carotid atherosclerosis development in patients with systemic lupus erythematosus. Baragetti A, Ramirez GA, Magnoni M, Garlaschelli K, Grigore L, Berteotti M, Scotti I, Bozzolo E, Berti A, Camici PG, Catapano AL, Manfredi AA, Ammirati E, Norata GD. Nutr Metab Cardiovasc Dis. 2018;28(1):53-63. IF 3.340
51. Targeting cholesterol in non-ischemic heart failure: a role for LDLR gene therapy? Catapano AL, Pirillo A, Norata GD. Mol Ther. 2017;25(11):2435-2437. IF 7.008
52. Strategies for the use of Non-Statin therapies. PirilloA, Norata GD, Catapano AL. Curr Opin Lipidol. 2017;28(6):458-464. IF 3.853
53. Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and prospectives. Catapano AL, Pirillo A, Norata GD. Vasc Health Risk Manag 2017;13:343-351.
54. PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans. Baragetti A, Balzarotti G, Grigore L, Pellegatta F, Guerrini U, Pisano G, Fracanzani AL, Fargion S, Norata GD, Catapano AL. Eur J Prev Cardiol. 2017;24(17):1870-1877. IF 4.542
55. Advances in Hypercholesterolemia. Pirillo A, Norata GD, Catapano AL. Medicinal Chemistry III vol. 7, pp. 663–93. Oxford: Elsevier
56. PCSK9 inhibition in statin-intolerant HeFH patients: What's new? Casula M, Pirillo A, Norata GD, Catapano AL. Eur J Prev Cardiol. 2017;24(14):1525-1527. IF 4.542
57. Arctigenin improves vascular tone and decreases inflammation in human saphenous vein. Daci A, Neziri B, Krasniqi S, Cavolli R, Alaj R, Norata GD, Beretta G. Eur J Pharmacol. 2017;810:51-56. IF 3.040
58. Automatic identification of variables in epidemiological datasets using logic regression. Lorenz MW, Abdi NA, Scheckenbach F, Pflug A, Bülbül A, Catapano AL, Agewall S, Ezhov M, Bots ML, Kiechl S, Orth A; PROG-IMT study group. BMC Med Inform Decis Mak. 2017;17(1):40.
59. Long pentraxin PTX3 as a prognostic marker of cardiovascular mortality in patients with chronic kidney disease. Baragetti A, Norata GD. Pol Arch Intern Med. 2017;127(3):152-153. IF 2.882
60. A past and present overview of macrophage metabolism and functional outcomes. Curi R, de Siqueira Mendes R, de Campos Crispin LA, Norata GD, Sampaio SC, Newsholme P. Clin Sci (Lond). 2017;131(12):1329-1342. IF 5.220
61. mTORC1 activity repression by late endosomal phosphatidylinositol 3,4-bisphosphate. Marat AL, Wallroth A, Lo WT, Müller R, Norata GD, Falasca M, Schultz C, Haucke V. Science. 2017;356(6341):968-972. IF 41.058
62. Vascular inflammation and low density lipoproteins: is cholesterol the link? A lesson from the clinical trials. Catapano AL, Pirillo A, Norata GD. Br J Pharmacol. 2017;174(22):3973-3985. IF 6.810
63. Translating the microRNA signature of microvesicles derived from human coronary artery smooth muscle cells in patients with familial hypercholesterolemia and coronary artery disease. De Gonzalo-Calvo D, Cenarro A, Garlaschelli K, Pellegatta F, Vilades D, Nasarre L, Camino-Lopez S, Crespo J, Carreras F, Leta R, Catapano AL, Norata GD, Civeira F, Llorente-Cortes V. J Mol Cell Cardiol 2017;106:55-67. IF 5.296
64. T follicular helper cells promote a beneficial gut ecosystem for host metabolic homeostasis by sensing microbiota derived extracellular ATP. Perruzza L, Gargari G, Proietti M, Fosso B, D’Erchia AM, Faliti CE, Rezzonico-Jost T, Scribano D, Mauri L, Colombo D, Pellegrini G, Moregola A, Mooser C, Pesole G, Nicoletti M, Norata GD, Geuking MB, McCoy KD, Guglielmetti S, Grassi F. Cell Rep. 2017;18(11):2566-2575.
IF 8.032
65. Obesity-induced metabolic stress leads to biased effector memory CD4+T cell differentiation via PI3K p110d/Akt-mediated signals. Mauro C, Smith J, Cucchi D, Coe D, Fu H, Bonacina F, Baragetti A, Cermenati G, Caruso D, Mitro N, Catapano AL, Ammirati E, Longhi MP, Okkenhaug K, Norata GD, Marelli-Berg FM. Cell Metab. 2017;25(3):593-609. IF 20.565
66. Translating the biology of adipokines in atherosclerosis and cardiovascular diseases: gaps and open questions. Ruscica M, Baragetti A, Catapano AL, Norata GD. Nutr Metab Cardiovasc Dis. 2017;27(5):379-395. IF 3.318
67. Circulating CD14+ and CD14highCD16- classical monocytes are reduced in patients with signs of plaque neovascularization in the carotid artery. Ammirati E, Moroni F, Magnoni M, Di Terlizzi S, Villa C, Sizzano F, Palini A, Garlaschelli K, Tripiciano F, Scotti I, Catapano AL, Manfredi AA, Norata GD, Camici PG. Atherosclerosis. 2016; 255:171-178. IF 4.239
68. Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering. Norata GD, Tavori H, Pirillo A, Fazio S, Catapano AL. Cardiovasc Res. 2016;112(1):429-442. IF 5.878
69. Genetically determined telomeres shortening is associated with carotid atherosclerosis progression and increased incidence of cardiovascular events. Baragetti A, Palmen J, Garlaschelli K, Grigore L, Humphries S, Talmud PJ, Catapano AL, Norata GD. Int J Cardiol. 2016;223:43-45. IF 6.189
70. Epicardial adipose tissue (EAT) thickness is associated with cardiovascular and liver damage in nonalcoholic fatty liver disease. Fracanzani AL, Pisano G, Baragetti A, Consonni D, Tiraboschi S, Bertelli C, Norata GD, Dongiovanni P, Valenti L, Grigore L, Tonella T, Catapano AL, Fargion S. PLoS One 2016;11(9):e0162473. IF 2.806
71. Vascular pentraxin 3 controls arterial thrombosis by targeting collagen and fibrinogen induced platelets aggregation. Bonacina F, Barbieri SS, Cutuli L, Amadio P, Doni A, Sironi M, Tartari S, Mantovani A, Bottazzi B, Garlanda C, Tremoli E, Catapano AL, Norata GD. Biochim Biophys Acta. 2016;1862(6):1182-1190. IF 5.476
72. Applicability of the 2013 ACC/AHA Risk Assessment and Cholesterol Treatment Guidelines in the Real World: Results from a Multiethnic Case-Control Study. Magnoni M, Berteotti M, Norata GD, Limite LR, Peretto G, Cristell N, Maseri A, Cianflone D. Ann Med. 2016;48(4):282-292. IF 3.715
73. Niemann-Pick C1-Like 1 (NPC1L1) inhibition and cardiovascular diseases. Pirillo A, Catapano AL, Norata GD. Curr Med Chem. 2016;23(10):983-999. IF 3.455
74. Progression of carotid vascular damage and cardiovascular events in non alcoholic fatty liver disease patients compared to the general population during 10 Years of follow-up. Fracanzani AL, Tiraboschi S, Pisano G, Consonni D, Baragetti A, Bertelli C, Norata GD, Valenti L, Grigore L, Porzio M, Catapano AL, Fargion S. Atherosclerosis 2016;246:208-213. IF 4.239
75. Normative values for carotid intima media thickness and its progression: Are they transferrable outside of their cohort of origin? Liao X, Norata GD, Polak JF, Stehouwer CD, Catapano A, Rundek T, Ezhov M, Sander D, Thompson SG, Lorenz MW; PROG-IMT study group. Eur J Prev Cardiol. 2016;23(11):1165-1173. IF 3.606
76. Subclinical atherosclerosis is associated with Epicardial Fat Thickness and hepatic steatosis in the general population. Baragetti A, Pisano G, Bertelli C, Garlaschelli K, Grigore L, Fracanzani AL, Fargion S, Norata GD, Catapano AL. Nutr Metab Cardiovasc Dis. 2016;26(2):141-153. IF 3.679
77. Longer genotypically-estimated leukocyte telomere length is associated with increased adult glioma risk. Walsh KM, Codd V, Rice T, Nelson CP, Smirnov IV, McCoy LS, Hansen HM, Elhauge E, Ojha J, Francis SS, Madsen NR, Bracci PM, Pico AR, Molinaro AM, Tihan T, Berger MS, Chang SM, Prados MD, Jenkins RB, Wiemels JL; ENGAGE Consortium Telomere Group, Samani NJ, Wiencke JK, Wrensch MR. Oncotarget. 2015 Dec 15;6(40):42468-42477. IF 5.008
78. Polymorphic Variants of SCN1A and EPHX1 Influence Plasma Carbamazepine Concentration, metabolism and pharmacoresistance in a population of kosovar albanian epileptic patients. Daci A, Beretta G, Vllasaliu D, Shala A, Govori V, Norata GD, Krasniqi S. PLoS One. 2015 Nov 10;10(11):e0142408. IF 3.057
79. The cellular and molecular basis of translational immunometabolism. Norata GD, Caligiuri G, Chavakis T, Matarese G, Netea MG, Nicoletti A, O'Neill LAJ, Marelli-Berg FM. Immunity. 2015;43(3):421-434. IF 24.082
80. Functional Analysis of a Carotid Intima-Media Thickness Locus Implicates BCAR1 and Suggests a Causal Variant. Boardman-Pretty F, Smith AJ, Cooper J, Palmen J, Folkersen L, Hamsten A, Catapano AL, Melander O, Price JF, Kumari M, Deanfield JE, Kivimäki M, Gertow K, Baragetti A, Norata GD, Humphries SE. Circ Cardiovasc Genet. 2015;8(5):696-706. IF 3.719
81. Apolipoprotein C-III: from pathophysiology to pharmacology. Norata GD, Tsimikas S, Pirillo A, Catapano AL. Trends Pharmacol Sci. 2015;36(10):675-687. IF 11.840
82. Carotid Intima Media Thickness progression and risk of vascular events in people with diabetes mellitus- results from the PROG-IMT collaboration. Lorenz MW, Price JF, Robertson C, Bots ML, Polak JF, Poppert H, Kavousi M, Dörr M, Stensland E, Ducimetiere P, Ronkainen K, Kiechl S, Sitzer M, Rundek T, Lind L, Liu J, Bergström G, Grigore L, Bokemark L, Friera A, Yanez D, Bickel H, Ikram MA, Völzke H, Johnsen SH, Empana JP, Tuomainen TP, Willeit P, Steinmetz H, Desvarieux M, Xie W, Schmidt C, Norata GD, Suarez C, Sander D, Hofman A, Schminke U, Mathiesen E, Plichart M, Kauhanen J, Willeit J, Sacco RL, McLachlan S, Zhao D, Fagerberg B, Catapano AL, Gabriel R, Franco OH, Bülbül A, Scheckenbach F, Pflug A, Gao L, Thompson SG. Diabetes Care 2015;38(10):1921-1929. IF 8.934
83. PI3K-C2γ 3 is a Rab5 effector selectively controlling endosomal Akt2 activation downstream insulin signaling. Braccini L, Ciraolo E, Campa CC, Perino A, Longo DL, Tibolla G, Pregnolato M, Cao Y, Tassone B, Damilano F, Laffargue M, Calautti E, Falasca M, Norata GD, Backer J, Hirsch E. Nat Commun. 2015;6:7400. IF 11.329
84. Peak inflammation in atherosclerosis, primary biliary cirrhosis and autoimmune arthritis is counter-intuitively associated with regulatory T cell enrichment. Garetto S, Trovato AE, Lleo A, Sala F, Martini E, Betz AG, Norata GD, Invernizzi P, Kallikourdis M. Immunobiology. 2015;220(8):1025-1029. IF 2.871
85. Markers of inflammation associated with plaque progression and instability in patients with carotid atherosclerotic. Ammirati E, Moroni F, Norata GD, Magnoni M, Camici PG. Mediators Inflamm. 2015;2015:718329. IF 3.418
86. An acidic microenvironment sets the humoral pattern recognition molecule PTX3 in a tissue repair mode. Doni A, Musso T, Morone D, Bastone A, Zambelli V, Sironi M, Castagnoli C, Cambieri I, Stravalaci M, Pasqualini F, Laface I, Valentino S, Tartari S, Ponzetta A, Maina V, Barbieri SS, Tremoli E, Catapano AL, Norata GD, Bottazzi B, Garlanda C, Mantovani A. J Exp Med. 2015;212(6):905-925. IF 11.240
87. IDOL N342S Variant, atherosclerosis progression and cardiovasculard disorders in the Italian general population. Dhyani A, Tibolla G, Baragetti A, Garlaschelli K, Pellegatta F, Grigore L, Norata GD, Catapano AL. PLoS One. 2015;10(4):e0122414.
IF 3.057
88. Fibronectin extra domain A stabilizes atherosclerotic plaque phenotype in apolipoprotein E and in LDL-receptor-deficient mice. Pulakazhi Venu VK, Uboldi P, Dhyani A, Patrini A, Baetta R, Nicola Ferri N, Corsini A, Andrés F. Muro F, Catapano AL, Norata GD. Thromb Haemost. 2015;114(1):186-197. IF 5.255
89. Homozygous familial hypobetalipoproteinemia: two novel mutations in the splicing sites of apolipoprotein B gene and review of the literature. Cefalù AB, Norata GD, Ghiglioni DG, Noto D, Uboldi P, Garlaschelli K, Baragetti A, Spina R, Valenti V, Pederiva C, Riva E, Terracciano L, Zoja A, Grigore L, Averna MR, Catapano AL. Atherosclerosis. 2015, 239(1):209-217. IF 3.942
90. HDL in Infectious Diseases and Sepsis. Pirillo A, Catapano AL, Norata GD. Handb Exp Pharmacol. 2015;224:483-508.
91. Impact of systemic inflammation and autoimmune diseases on apoA-I and HDL plasma levels and functions. Montecucco F, Favari E, Norata GD, Ronda N, Nofer J, Vuilleumier N. Handb Exp Pharmacol. 2015;224:455-482.
92. Inflammatory markers and extent and progression of early atherosclerosis: meta-analysis of individual-participant-data from 20 prospective studies of the PROG-IMT collaboration. Willeit P, Thompson SG, Agewall S, Bergström G, Bickel H, Catapano AL, Chien KL, de Groot E, Empana JP, Etgen T, Franco OH, Iglseder B, Johnsen SH, Kavousi M, Lind L, Liu J, Mathiesen EB, Norata GD, Olsen MH, Papagianni A, Poppert H, Price JF, Sacco RL, Yanez DN, Zhao D, Schminke U, Bülbül A, Polak JF, Sitzer M, Hofman A, Grigore L, Dörr M, Su TC, Ducimetière P, Xie W, Ronkainen K, Kiechl S, Rundek T, Robertson C, Fagerberg B, Bokemark L, Steinmetz H, Arfan Ikram M, Völzke H, Lin HJ, Plichart M, Tuomainen TP, Desvarieux M, McLachlan S, Schmidt C, Kauhanen J, Willeit J, Lorenz MW, Sander D; for the PROG-IMT study group. Eur J Prev Cardiol. 2016;23(2):194-205. IF 3.361
93. The arachidonic acid metabolome serves as a conserved regulator of cholesterol metabolism. Demetz E, Schroll A, Auer K, HeimC, Patsch JR, Eller P, Theurl M, Theurl I, Theurl M Seifert M, Lener D, Stanzl U, Haschka D, Asshoff M, Dichtl S, Nairz M, Huber E, Stadlinger M, Li X, Pallweber P, Scharnagl H, Stojakovic T, März W,. Kleber ME, Garlaschelli K, Uboldi P, Catapano AL, Stellaard F, Rudling M, Kuba K, Imai Y, Arita M, Pramstaller PP, Tietge UJF, Trauner M, Norata GD, Claudel T, Hicks AA, Weiss G, Tancevski I. Cell Metab. 2014;20(5):787-798. IF 17.565
94. PCSK9 inhibition for the treatment of hypercholesterolemia: promises and emerging challenges. Norata GD, Tibolla G, Catapano AL. Vascul Pharmacol. 2014;62(2):103-111. IF 3.635
95. Variants near TERT and TERC influencing telomere length are associated with high-grade glioma risk. Walsh KM, Codd V, Smirnov IV, Rice T, Decker PA, Hansen HM, Kollmeyer T, Kosel ML, Molinaro AM, McCoy LS, Bracci PM, Cabriga BS, Pekmezci M, Zheng S, Wiemels JL, Pico AR, Tihan T, Berger MS, Chang SM, Prados MD, Lachance DH, O'Neill BP, Sicotte H, Eckel Passow JE; ENGAGE Consortium Telomere Group, van der Harst P, Wiencke JK, Samani NJ, Jenkins RB, Wrensch MR. Collaborators: Codd V, Nelson CP, Albrecht E, Mangino M, Deelen J, Buxton JL, Hottenga JJ, Fischer K, Esko T, Surakka I, Broer L, Nyholt DR, Leach IM, Salo P, Hägg S, Matthews MK, Palmen J, Norata GD, O'Reilly PF, Saleheen D, Amin N, Balmforth AJ, Beekman M, de Boer RA, Böhringer S, Braund PS, Burton PR, de Craen AJ, Denniff M, Dong Y, Douroudis K, Dubinina E, Eriksson JG, Garlaschelli K, Guo D, Hartikainen AL, Henders AK, Houwing-Duistermaat JJ, Kananen L, Karssen LC, Kettunen J, Klopp N, Lagou V, van Leeuwen EM, Madden PA, Mägi R, Magnusson PK, Männistö S, McCarthy MI, Medland SE, Mihailov E, Montgomery GW, Oostra BA, Palotie A, Peters A, Pollard H, Pouta A, Prokopenko I, Ripatti S, Salomaa V, Suchiman H, Valdes AM, Verweij N, Viñuela A, Wang X, Wichmann HE, Widen E, Willemsen G, Wright MJ, Xia K, Xiao X, van Veldhuisen DJ, Catapano AL, Tobin MD, Hall AS, Blakemore AI, van Gilst WH, Zhu H, Erdmann J, Reilly MP, Kathiresan S, Schunkert H, Talmud PJ, Pedersen NL, Perola M, Ouwehand W, Kaprio J, Martin NG, van Duijn CM, Hovatta I, Gieger C, Metspalu A, Boomsma DI, Jarvelin MR, Slagboom P, Thompson JR, Spector TD, van der Harst P, Samani NJ. Nat Genet. 2014;46(7):731-735. IF 29.352
96. Inibitori di PCSK9 e dislipidemie: le evidenze cliniche. Norata GD. G Ital Cardiol 2014;15(5):301-305.
97. HDL in innate and adaptive immunity. Catapano AL, Pirillo A, Bonacina F, Norata GD. Cardiovasc Res. 2014;103(3):372-383. IF 5.940
98. Pentraxins and Atherosclerosis. Barbati E, Bottazzi B, Catapano AL, Garlanda C, Latini R, Mantovani A, Norata GD, Valentino S. 2014 Inflammation and Atherosclerosis, pp 219-237
99. PCSK9 inhibitors and dyslipidemia: The clinical evidence. Norata GD. Giornale Italiano di Cardiologia. 2014;15:301-305.
100. Telomere shortening over 6 years is associated with increased subclinical carotid vascular damage and worse cardiovascular prognosis in the general population: results from the PLIC study. Baragetti A, Palmen J, Garlaschelli K, Grigore L, Pellegatta F, Tragni, E, Catapano AL, Humphries S, Norata GD, Talmud PJ. J Intern Med. 2015;277(4):478-487. IF 7.803
101. Novel concepts in HDL pharmacology. Remaley AT, Norata GD, Catapano AL. Cardiovasc Res. 2014;103(3):423-428. IF 5.940
102. New therapeutic principles for familial hypercholesterolemia. Norata GD. Clin Biochem. 2014;47(9):756. IF 2.275
103. MiR-143/145 deficiency attenuates the progression of atherosclerosis in Ldlr-/- mice. Sala F, Aranda JF, Rotllan N, Ramírez CM, Aryal B, Elia L, Condorelli G, Catapano AL, Fernández-Hernando C, Norata GD. Thromb Haemost. 2014;112(24);796-802.
IF 4.984
104. Statins and skeletal muscles toxicity: from clinical trials to everyday practice. Norata GD, Tibolla G, Catapano AL. Pharmacol Res. 2014;88:107-113. IF 4.408
105. HDL to treat or not to treat? Pirillo A, Norata GD, Catapano AL. Curr Ath Rep. 2014;16(8):429. IF 3.417
106. Statins and periodontal inflammation: a pleiotropic effect of statins or a pleiotropic effect of LDL-cholesterol lowering? Norata GD, Catapano AL. Atherosclerosis. 2014;234(2):381-382. IF 3.994
107. Postprandial lipidemia as a cardiometabolic risk factor. Pirillo A, Norata GD, Catapano AL. Curr Med Res Opin. 2014;30(8):1489-1503. IF 2.653
108. Cardiometabolic and immune factors associated with increased common carotid artery Intima Media Thickness and cardiovascular diseases in patients with systemic lupus erythematous. Ammirati E, Bozzolo EO, Contri R, Baragetti A, Palini AG, Cianflone D, Banfi M, Uboldi P, Scotti I, Pirillo A, Grigore L, Garlaschelli K, Monaco C, Catapano AL, Sabbadini MG, Manfredi AA, Norata GD. Nutr Metab Cardiovasc Dis. 2014;24(7):751-759. IF 3.323
109. The missing link between high-density lipoprotein cholesterol and inflammatory response in cardiovascular disease. Ammirati E, Scotti I, Norata GD. J Am Coll Cardiol. 2014;63(24):2747-2748. IF 16.503
110. Pentraxin 3 (PTX3) plasma levels and carotid intima media thickness progression in the general population. Baragetti A, Knoflach M, Cuccovillo I, Grigore L, Casula M, Garlaschelli K, Mantovani A, Wick G, Kiechl S, Willeit J, Bottazzi B, Catapano AL, Norata GD. Nutr Metab Cardiovasc Dis. 2014;24(5):518-523. IF 3.323
111. Nonalcoholic fatty liver and metabolic syndrome in Italy: results from a multicentric study of the Italian Arteriosclerosis society. Soresi M et al., on behalf of the Metabolic Syndrome Study Group. Acta Diabetologica. 2013;50(2):241-249. IF 2.679
112. The thyroid receptor modulator KB3495 reduces atherosclerosis independently of total cholesterol in the circulation in ApoE deficient mice. Mork LM, Rehnmark S, Davoodpour P, Norata GD, Larsson L, Witt MR, Malm J, Parini P. PLoS One. 2013;8(12):e78534. IF 3.534
113. Targeting PCSK9 for hypercholesterolemia. Norata GD, Tibolla G, Catapano AL. Annu Rev Pharmacol Toxicol. 2014;54:273-293. IF 18.365
114. The long pentraxin PTX3: a biomarker spanning from cardiovascular to cancer. Falasca M, Bonacina F, Catapano AL, Norata GD. J Mol Biomark Diagn. 2013;4:2.
115. LOX-1, OxLDL and atherosclerosis. Pirillo A, Norata GD, Catapano AL. Mediators Inflamm. 2013;2013:152786. IF 2.417
116. New targets and developments in lipoproteins control. Norata GD. Research Reports in Clinical Cardiology 2013;4:77-84.
117. The CD1d‐Natural Killer T cell axis in atherosclerosis. Bondarenko S, Catapano AL, Norata GD. J Innate Immun. 2014;6(1):3-12. IF 4.557
118. Prevalence of classical CD14++/CD16‐ but not of intermediate CD14++/CD16+ monocytes in hypoalphalipoproteinemia. Sala F, Cutuli L, Grigore G, Pirillo A, Chiesa G, Catapano AL, Norata GD. Int J Cardiol. 2013;168(3):2886-2889.
IF 6.175
119. High density lipoproteins cholesterol levels are an independent predictor of the progression of chronic kidney disease. Baragetti A, Norata GD, Sarcina C, Rastelli F, Grigore L, Garlaschelli K, Uboldi P, Baragetti I, Pozzi C, Catapano AL. J Intern Med. 2013;274(3):252-262. IF 5.785
120. Long pentraxin 3 (PTX3): experimental and clinical relevance in cardiovascular diseases. Bonacina F, Baragetti A, Catapano AL, Norata GD. Mediators Inflamm. 2013;2013:725102. IF 2.417
121. New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs. Norata GD, Ballantyne CM, Catapano AL. Eur Heart J. 2013;34(24):1783-1789.
IF 14.723
122. Gene silencing approaches for the management of dyslipidemia. Norata GD, Tibolla G, Catapano AL. Trends Pharmacol Sci. 2013;34(4):198‐205. IF 9.988
123. -374 T/A RAGE polymorphism is associated with chronic kidney disease progression in subjects affected by a nephrocardiovascular disease. Baragetti I, Norata GD, Sarcina C, Baragetti A, Rastelli F, Buzzi L, Grigore L, Garlaschelli K, Pozzi C, Catapano AL. PLoS One. 2013; 8(4):e60089. IF 3.534
124. LDL Lowering Drugs: Current Perspectives. Norata GD. Cardiovascular Pharmacology 2012;2(1):1000e104.
125. European Lipoprotein Club: Report of the 35th ELC Annual Conference. Costet P, Ehrenborg E, Fisher R, Fielding B, Groen A, Kardassis D, Malle E, Mulder M, Niemeier A, Norata GD, Hansen AT, Eckardstein Av. Atherosclerosis. 2013;226(2):510‐516. IF 3.971
126. High-density lipoprotein subfractions-what the clinicians need to know. Pirillo A, Norata GD, Catapano AL. Cardiology. 2013;124:116‐125. IF 2.044
127. Class II Phosphoinositide 3‐kinases contribute to endothelial cells morphogenesis. Tibolla G, Piñeiro R, Chiozzotto D, Mavrommati I, Wheeler AP, Norata GD, Catapano AL, Maffucci T, Falasca M. PLoS One. 2013;8(1):e53808.
IF 3.534
128. The zebrafish embryo derivative affects cell viability of epidermal cells: a possible role in the treatment of psoriasis. Norata GD, Biava PM, Di Pierro F. Giornale Ital. Dermatol. Venereol. 2013, 148 (5):479–483.
129. MicroRNAs and lipoproteins: a connection beyond atherosclerosis? Norata GD, Sala F, Catapano AL, Fernández‐Hernando C. Atherosclerosis 2013;227(2):209‐215.
IF 3.971
130. Identification of seven loci affecting mean telomere length and their association with disease. Codd V, Nelson CP, Albrecht E, Mangino M, Deelen J, Buxton JL, Hottenga JJ, Fischer K, Esko T, Surakka I, Broer L, Nyholt DR, Leach IM, Salo P, Hägg S, Matthews MK, Palmen J, Norata GD, O’Reilly PF, Saleheen D, Amin N, Balmforth AJ, Beekman M, de Boer RA, Böhringer S, Braund PS, Burton PR, de Craen AJM, Denniff M, Dong Y, Douroudis K, Dubinina E, Eriksson JG, Garlaschelli K, Guo D, Hartikainen AL, Henders AK, Houwing‐ Duistermaat JJ, Kananen L, Karssen LC, Kettunen J, Klopp N, Lagou V, van Leeuwen EM, Madden P, Mägi R, Magnusson PKE, Männistö S, McCarthy MI, Medland SE, Mihailov E, Montgomery GW, Oostra BA, Palotie A, Peters A, Pollard H, Pouta A, Prokopenko I, Ripatti S, Salomaa V, Suchiman HED, Valdes AM, Verweij N, Vinuela A, Wang X, Wichmann HE, Widen E, Willemsen G, Wright MJ, Xia K, Xiao X, van Veldhuisen DJ, Catapano AL, Tobin MD, Hall AS, Blakemore AIF,van Gilst WH, Zhu H, CARDIoGRAM consortium, Erdmann J, Reilly MP, Kathiresan S, Schunkert H, Talmud PJ, Pedersen NL, Perola M,, Ouwehand W, Kaprio J, Martin NG, van Duijn CM, Hovatta I, Gieger C, Metspalu A, Boomsma D, Jarvelin MR, Slagboom PE, Thompson JR, Spector TD, van der Harst P, Samani NJ. Nat Genet. 2013;45(4):422‐427. IF 29.648
131. Pharmacogenetics in cardiovascular disorders: an update on the principal drugs. Predazzi IM, Mango R, Norata GD, Di Daniele N, Sergi D, Romeo F, Novelli G. Am J Cardiovasc Drugs. 2013;13(2):79‐85. IF 2.203
132. High density lipoproteins and atherosclerosis: emerging aspects. Sala F, Catapano AL, Norata GD. J Geriatr Cardiol. 2012;9(4):401‐407.
133. Treating high density lipoprotein cholesterol (HDL‐C): quantity versus quality. Pirillo A, Norata GD, Catapano AL. Curr Pharm Des. 2013;19(21):3841-3857. IF 3.288
134. Established and Emerging Approaches for The Management of Dyslipidaemia. Norata GD. Scientifica 2012;2012:482423.
135. HDL and adaptive immunity: a tale of lipid rafts. Norata GD, Catapano AL. Atherosclerosis 2012;225(1):34‐35. IF 3.706
136. Effects of treatment with pravastatin or ezetimibe on endothelial function in patients with moderate hypercholesterolemia. Grigore G, Raselli S, Garlaschelli K, Redaelli L, Norata GD, Pirillo A, Catapano AL. Eur J Clin Pharmacol. 2013;69(3):341‐346. IF 2.741
137. Antigen-dependent and antigen-independent pathways modulate CD4+CD28null T cells during atherosclerosis. Ammirati E, Monaco C, Norata GD. Circ Res. 2012;111(2):e48‐e49. IF 11.861
138. Carotid intima‐media thickness progression to predict cardiovascular events in the general population (the PROG‐IMT collaborative project): a meta‐analysis of individual participant data. Lorenz MW et al, on behalf of the PROG‐IMT Study Group. Lancet 2012;379(9831):2053‐2062. IF 39.060
139. A CYP26B1 polymorphism enhances retinoic acid catabolism which may aggravate atherosclerosis. Krivospitskaya O, Elmabsout AA, Sundman E, Söderström LA, Ovchinnikova O, Gidlöf AC, Scherbak N, Norata GD, Samnegård A, Törmä H, Abdel‐Halim SM, Jansson JH, Eriksson P, Sirsjö A and Olofsson PS. Mol Med. 2012;18:712‐718. IF 4.469
140. Leonurine: a new comer in the natural compounds affecting atherosclerosis. Norata GD, Catapano AL. Atherosclerosis. 2012;224(1):37‐38. IF 3.706
141. MicroRNA 143‐145 deficiency impairs vascular function. Norata GD, Pinna C, Zappella F, Elia L, Sala A, Condorelli G, Catapano AL. Int J Immunopathol Pharmacol. 2012;25(2);467‐484. IF 2.685
142. LOX-1 Inhibition in ApoE KO Mice Using a Schizophyllan-based Antisense Oligonucleotide Therapy. Amati F, Diano L, Vecchione L, Norata GD, Koyama Y, Cutuli L, Catapano AL, Romeo F, Ando H, Novelli G. Mol Ther Nucleic Acids. 2012;1:e58.
143. Effect of Tie‐2 conditional deletion of BDNF on atherosclerosis in the ApoE null mutant mouse. Norata GD, Pulakazhi Venu VK, Callegari E, Paloschi V, Catapano AL. Biochim Biophys Acta ‐ Mol Basis Dis. 2012;1822(6):927‐935. IF 4.910
144. Long pentraxin 3/tumor necrosis factor-stimulated gene-6 interaction a biological rheostat for fibroblast growth factor 2‐mediated angiogenesis. Leali D, Inforzato A, Ronca R, Belleri M, Coltrini D, Bianchi R, Di Salle E, Sironi M, Norata GD, Bottazzi B, Garlanda C, Day AJ, Presta M. Arterioscler Thromb Vasc Biol. 2012;32(3):696‐670.
IF 6.338
145. Effector memory T cells are associated with atherosclerosis in humans and animal models.Ammirati E, Cianflone D, Vecchio V, Banfi M, Vermi AC, De Metrio M, Grigore L, Pellegatta F, Pirillo A, Garlaschelli K, Manfredi AA, Catapano AL, Maseri A, Palini A, Norata GD. J Am Heart Assoc. 2012;1(1):27‐41.
146. Association between OLR1 K167N SNP and intima media thickness of the common carotid artery in the general population. Predazzi IM, Norata GD, Vecchione L, Garlaschelli K, Amati F, Grigore G, Cutuli L, Pirillo A, Romeo F, Novelli G, Catapano AL. PLoS One. 2012;7(2):e31086. IF 3.730
147. Association between the adherence to AHA Step 1 nutrition criteria and the cardiometabolic outcome in the general population a two year follow‐up study. Redaelli L, Garlaschelli K, Grigore G, Norata GD, Catapano AL. Food and Nutrition Sciences. 2012;3:274‐280.
148. Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure‐function relation to therapeutic inhibition. Tibolla G, Norata GD, Artali R, Meneghetti F, Catapano AL. Nutr Metab Cardiovasc Dis. 2011;21(11):835‐843. IF 3.731
149. The androgen derivative 5α-androstane-3β,17β-diol inhibits tumor necrosis factor α and lipopolysaccharide induced inflammatory response in human endothelial cells and in mice aorta. Norata GD, Cattaneo P, Poletti A, Catapano AL. Atherosclerosis. 2010; 212:100‐6. IF 4.086
150. HDLs, immunity, and atherosclerosis. Norata GD, Pirillo A, Catapano AL. Curr Opin Lipidol. 2011;22(5):410‐416. IF 6.086
151. Emerging role of high density lipoproteins as a player in the immune system. Norata GD, Pirillo A, Ammirati E, Catapano AL. Atherosclerosis 2012;220(1):11‐21.
IF 3.794
152. Therapy and clinical trials: aggressive statin therapy vs combined and emerging approaches. Catapano AL, Norata GD, Pirillo A. Curr Opin Lipidol. 2011;22(4):324‐325. IF 6.086
153. Immunità ed aterosclerosi: aspetti emergenti. Norata GD, Ammirati E, Cutuli L, Catapano AL. Il Giornale dell’Aterosclerosi. 2011;1:13‐24.
154. Novel biotinylated bile acid amphiphiles: micellar aggregates formation and interaction with hepatocytes. Rizzi L, Braschi M, Colombo M, Vaiana N, Tibolla G, Norata GD, Catapano AL, Romeo S, Propseri D. Org Biomol Chem. 2011;9(8):2899‐2905. IF 3.696
155. Circulating CD4+CD25hiCD127lo regulatory T‐cell levels do not reflect the extent or severity of carotid and coronary atherosclerosis. Ammirati E, Cianflone D, Banfi M, Vecchio V, Palini A, De Metrio M, Marenzi G, Panciroli C, Tumminello G, Anzuini A, Palloshi A, Grigore L, Garlaschelli K, Tramontana S, Tavano D, Airoldi F, Manfredi AA, Catapano AL, Norata GD. Arterioscler Thromb Vasc Biol. 2010; 30(9):1832‐1841.
IF 7.215
156. The long pentraxin PTX3: a modulator of the immuno‐inflammatory response in atherosclerosis and cardiovascular diseases. Norata GD, Garlanda C, Catapano AL. Trends Cardiovasc Med. 2010;20(2):35‐40. IF 3.250
157. Individual progression of carotid intima media thickness as a surrogate for vascular risk (PROG‐IMT) ‐ rationale and design of a meta‐analysis project. Lorenz MW, Bickel H, Bots ML, Breteler MMB, Catapano AL, Desvarieux M, Hedblad B, Iglseder B, Johnsen SH, Juraska M, Kiech S, Mathiesen EB, Norata GD, Grigore L, Polak J, Poppert H, Rosvall M, Rundek T, Sacco RL, Sander D, Sitzer M, Steinmetz H, Stensland E, Willeit J, Witteman J, Yanez D, Thompson SG, Prof. The PROG‐IMT Study Group. Am Heart J. 2010;159(5):730‐736. IF 5.052
158. Lecithin:Cholesterol Acyltransferase and vascular disease. Norata GD, Catapano AL. Clinical Lipidology. 2010;5:13-15.
159. Increased atherosclerosis and vascular inflammation in APP transgenic mice with Apolipoprotein E deficiency. Tibolla G, Norata GD, Meda C, Arnaboldi L, Uboldi P, Piazza F, Ferrarese C, Corsini A, Maggi A, Vegeto E, Catapano AL. Atherosclerosis. 2010;210(1):78‐87. IF 4.086
160. Effects of PCSK9 variants on common carotid artery intima media thickness and relation to ApoE alleles. Norata GD, Garlaschelli K, Grigore L, Raselli S, Tramontana S, Meneghetti F, Artali R, Noto D, Cefalù AD, Buccianti G, Averna M, Catapano AL. Atherosclerosis. 2010;208(1):177‐182. IF 4.086
161. Cholesterol absorption inhibitors. Norata GD, Catapano AL. 2009 Clinical Lipidology: a Companion to Braunwald's Heart Disease. Pp. 288-297
162. Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis. Norata GD, Marchesi P, Pulakazhi Venu VK, Pasqualini F, Anselmo A, Moalli F, Pizzitola I, Garlanda C, Mantovani A, Catapano AL. Circulation. 2009;120(8):699‐708. IF 14.816
163. Small dense LDL and VLDL predict common carotid artery IMT and elicit an inflammatory response in peripheral blood mononuclear and endothelial cells. Norata GD, Raselli S, Grigore L, Garlaschelli K, Vianello D, Bertocco S, Zambon A, CatapanoAL. Atherosclerosis. 2009;206(2):556‐562. IF 4.522
164. Plasma adiponectin levels in chronic kidney disease patients: relation with molecular inflammatory profile and metabolic status. Norata GD, Baragetti I, Raselli S, Stucchi A, Garlaschelli K, Vettoretti S, Piloni G, Buccianti G, Catapano AL. Nutr Metab Cardiovasc Dis. 2010;20(1):56‐63. IF 3.438
165. La microalbuminuira è un marcatore indipendente di danno cardiovascolare subclinico in soggetti affetti da disfunzione renale cronica. Baragetti I, Buzzi L, Stucchi A, Sarcina C, Buccianti G, Catapano AL, Norata GD. Il Bassini; volume XXVIII Gennaio‐Giugno 2008;26‐31.
166. Circulating soluble receptor for advance glycation end products is inversely associated with body mass index and waist/hip ratio in the general population. Norata GD, Garlaschelli K, Grigore L, Tibolla G, Raselli S, Redaelli L, Buccianti G, Catapano AL. Nutr Metab Cardiovasc Dis. 2009;19(2):129‐134. IF 3.517
167. Il tessuto adiposo come possibile bersaglio di danno cardiovascolare in corso di disfunzione renale. Baragetti I, Norata GD, Raselli S, Stucchi A, Terranno V, Catapano AL, Buccianti G. Il Bassini; volume XXVII Luglio‐Dicembre 2007;9‐13.
168. Long pentraxin 3, a key component of innate immunity, is modulated by high density lipoproteins in endothelial cells. Norata GD, Marchesi P, Pirillo A, Uboldi P, Chiesa G, Maina V, Garlanda C, Mantovani A, Catapano AL. Arterioscl Thromb Vasc Biol. 2008;28(5):925‐931. IF 6.858
169. The relationship between leptin: Adiponectin ratio and carotid intima‐media thickness in asymptomatic females ‐ Response to letter by Kotani et al. Norata GD, Magni P, Catapano AL. Stroke 2008;39:e34. IF 6.499
170. Combination therapy in cholesterol reduction: focus on ezetimibe and statins. Grigore L, Norata GD, Catapano AL. Vasc Health Risk Manag. 2008;4(2):1‐12.
171. Inhibition of synthesis and absorption of cholesterol: a new option in managing hypercholesterolemia. Grigore L, Norata GD, Catapano AL. International Congress Series 2007;1303:121‐128.
172. Leptin:adiponectin ratio is an independent predictor of intima‐media thickness of the common carotid artery. Norata GD, Raselli S, Grigore L, Garlaschelli K, Dozio E, Magni P, Catapano AL. Stroke 2007;38(10):2844‐2846. IF 6.296
173. ApoE gene delivery inhibits severe hypercholesterolemia in newborn ApoE‐KO mice. Signori E, Rinaldi M, Fioretti D, Iurescia S, Seripa D, Perrone G, Norata GD, Catapano AL, Fazio VM. Biochem Biophys Res Comm. 2007;361(2):543‐548.
IF 2.749
174. Associazione tra polimorfismo –374T/A del RAGE e gravità dela disfunzione renale in pazienti affetti da insufficienza renale cronica (IRC). Stucchi A, Terranno V, Baragetti I, Tibolla G, Vettoretti S, Raselli S, Norata GD, Buzzi L, Catapano AL, Buccianti G. Il Bassini 2007; XXVII;12‐17.
175. Triglyceride‐rich lipoproteins from normotriglyceridemic subjects and hyperlipidemic patients differently affect endothelial cell activation and gene expression patterns. Norata GD, Catapano AL. Circ Res. 2007;100(7):e81. IF 9.721
176. Triglyceride‐rich lipoproteins and endothelial dysfunction: molecular mechanisms and gene expression studies. Norata GD, Catapano AL. Future Lipidology 2007;2;119‐122.
177. Effect of the -420C/G variant of the resistin gene promoter on metabolic syndrome, obesity, myocardial infarction and renal dysfunction. Norata GD, Ongari M, Garlaschelli K, Tibolla G, Grigore L, Raselli S, Vettoretti S, Baragetti I, Noto D, Cefalù AB, Buccianti G, Averna M , AL Catapano. J Intern Med. 2007;262(1):104‐112.
IF 4.901
178. Plasma resistin levels correlate with determinants metabolic syndrome. Norata GD, Ongari M, Garlaschelli K, Raselli S, Grigore L, Catapano AL. Eur J Endocrinol. 2007;156(2):279‐284. IF 3.239
179. Post‐prandial endothelial dysfunction in hypertriglyceridemic subjects: molecular mechanisms and gene expression studies. Norata GD, Grigore L, Raselli S, Redaelli L, Hamsten A, Maggi F, Eriksson P, Catapano AL. Atherosclerosis. 2007;193(2):321‐327.
IF 4.287
180. Anti‐inflammatory and anti‐atherogenic effects of cathechin, caffeic acid and trans-resveratrol in apolipoprotein E deficient mice. Norata GD, Marchesi P, Passamonti S, Pirillo A, Violi F, Catapano AL. Atherosclerosis. 2007;191(2):265‐271. IF 4.287
181. Effects of fractalkine receptor variants on common carotid artery intima‐media thickness. Norata GD, Garlaschelli K, Ongari M, Raselli S, Grigore L, Catapano AL. Stroke. 2006;37(6):1558‐1561. IF 5.391
182. Oxidized‐HDL3 modulates the expression of Cox‐2 in human endothelial cells. Callegari E, Norata GD, Inoue H, Catapano AL. Int J Mol Med. 2006;18(1):209‐13.
IF 1.867
183. HDL and endothelial function: from molecular mechanisms to clinical observations. Norata GD, Raselli S, Catapano AL. Future Lipidology 2006;1:343‐355.
184. Triglyceride‐rich lipoproteins from hypertriglyceridemic subjects induce a proinflammatory response in the endothelium: molecular mechanisms and gene expression studies. Norata GD, Grigore L, Raselli S, Seccomandi P, Hamsten A, Maggi FM, Eriksson P, Catapano AL. J Mol Cell Cardiol. 2006;40(4):484‐494. IF 4.859
185. In vitro isolation of circulating endothelial progenitor cells is related to high density lipoprotein plasma levels. Pellegatta F, Bragheri M, Grigore L, Raselli S, Maggi FM, Brambilla C, Reduzzi A, Pirillo A, Norata GD, Catapano AL. Intern J Mol Med. 2006;17(2):203‐208. IF 1.854
186. Modified HDL: biological and physiopathological consequences. Norata GD, Pirillo A, Catapano AL. Nutr Metab Cardiovasc Dis. 2006;16(5):371‐386. IF 1.867
187. Dihydrotestosterone decreases tumor necrosis factor a and lipopolysaccharide induced endothelial inflammatory response. Norata GD, Tibolla G, Seccomandi PM, Poletti A, Catapano AL. J Clin Endocrinol Metab. 2006;91(2):546‐554. IF 5.799
188. Effect of the Toll-like receptor 4 (TLR-4) variants on intima-media thickness and monocyte-derived macrophage response to LPS. Norata GD, Garlaschelli K, Ongari M, Raselli S, Grigore L, Benvenuto F, Maggi FM, Catapano AL. J Intern Med. 2005;258(1):1‐7. IF 4.040
189. Liver X receptor and retinoic X receptor agonist modulate the expression of genes involved in lipid metabolism in human endothelial cells. Norata GD, Ongari M, Uboldi P, Pellegatta F, Catapano AL. Intern J Mol Med. 2005;16(4):717‐723. IF 2.090
190. Molecular mechanisms responsible for the anti‐inflammatory and protective effect of HDL on the endothelium. Norata GD, Catapano AL. Vasc Health Risk Manag. 2005;1(2):119‐129.
191. High‐density lipoproteins induce transforming growth factor beta 2 expression in human endothelial cells. Norata GD, Callegari E, Marchesi M, Chiesa G, Eriksson P, Catapano AL. Circulation. 2005;111(21):2805‐2811. IF 11.632
192. Oxidized‐HDL3 induces the expression of PAI‐1 in human endothelial cells. Role of p38 MAPK activation and mRNA stabilization. Norata GD, Banfi C, Pirillo A, Tremoli E, Hamsten A, Catapano AL, Eriksson P. Br J Haematol. 2004;127(1):97‐104.
IF 3.195
193. Matrix metalloproteinase‐26 (matrylisin‐2) expression in high in endometrial hyperplasia and decreases with loss of histologic differentiation in endometrial cancer. Pilka R, Norata GD, Domanski H, Hansson S, Eriksson P, Casslen B. Gynecol Oncol. 2004; 94(3):661‐670. IF 2.083
194. Native LDL and Ox‐LDL modulate cyclooxygenase‐2 expression in HUVECs through a p38‐MAPK NF‐kB, CRE dependent pathways and ffects on PGE2 synthesis. Norata GD, Pirillo A, Pellegatta F, Inoue H, Catapano AL. Int J Mol Med. 2004;14(3):353‐359. IF 3.190
195. Tryglicerides rich lipoproteins and atherosclerosis: in vitro and in vivo studies. Norata GD, Raselli S, Grigore L, Maggi FM, Catapano AL. International Congress Series, 2004;1262:507‐510.
196. HDL3 induce cyclooxygenase‐2 expression and prostacyclin release in human endothelial cells via a p38 MAPK/CRE dependent pathway: Effects on COX‐2/PGI‐S coupling. Norata GD, Callegari E, Inoue H, Catapano AL. Arterioscler Thromb Vasc Biol. 2004;24(5):871‐877. IF 7.432
197. High density lipoprotein subfracion 3 decreases ADAMTs-1 expression induced by LPS and TNFα in human endothelial cells. Norata GD, Bjork H, Hamsten A, Catapano AL, Eriksson P. Matrix Biol. 2004;22(7):557‐560. IF 4.104
198. Lipid lowering activity of drugs affecting cholesterol absorption. Norata GD, Catapano AL. Nutr Metab Cardiovasc Dis. 2004;14(1):42‐51. IF 1.253
199. Gene expression and intracellular pathways involved in endothelial dysfunction induced by VLDL and oxidised VLDL. Norata GD, Pirillo A, Callegari E, Hamsten A, Catapano AL, Eriksson P. Cardiovasc Res. 2003;59(1):169‐180. IF 5.164
200. Effects of HDL3 on the expression of matrix-degrading proteases in human endothelial cells. Norata GD, Pellegatta F, Hamsten A, Catapano AL, Eriksson P. Int J Mol Med. 2003;12(1):73‐78. IF 1.940
201. Statins and oxidative stress during atherogenesis. Norata GD, Pirillo A , Catapano AL. Eur J Prev Cardiol. 2003;10(3):181‐9. IF 1.990
202. PPARs e Patologie Cardiovascolari. Norata GD, Pellegatta F, Catapano AL. Ital Heart J Suppl. 2003;4:8‐18.
203. Peroxisome proliferation activated receptors and cardiovascular disease. Norata GD, Pellagatta F, Catapano AL. Ital Heart J Suppl. 2003;4(1):8-18.
204. Apoptosis and proliferation of endothelial cells in early atherosclerotic lesions: a possible role for oxidized LDL. Norata GD, Tonti L, Roma P, Catapano AL. Nutr Metab Cardiovasc Dis. 2002;12(5):297‐305. IF 1.679
205. Lipoproteine ossidate e endotelio. Pirillo A, Norata GD, Catapano AL. Giornale dellʹAterosclerosi. 2002;27:53‐57.
206. Overexpression of Inducible Heat Shock Protein 70in COS-1 cells fails to protect from cytotoxicity of oxidized LDLs. Pirillo A, Norata GD, Zanelli T, Catapano AL. Arterioscler Thromb Vasc Biol. 2001;21(3):348‐354. IF 5.816
207. Oxidized lipoproteins and endothelium. Pirillo A, Zhu W, Norata GD, Zanelli T, Barberi L, Roma P, Catapano AL. Clin Chem Lab Med. 2000;38(2):155‐160. IF 1.744
Riconoscimenti e premi
2010: Premio giovani ricercatori European Atherosclerosis Society
2010: Premio giovani ricercatori MAJORS: the Metabolic Atherosclerotic Joint Regional
Symposium, Dublino
2009: Premio SISA per giovani ricercatori
2006: Premio giovani ricercatori SISA
2005: Premio giovani ricercatori consegnato da European Lipoprotein Club
2004: Premio giovani ricercatori SISA e SISA Lombardia
2003: Premio giovani ricercatori SISA 2002: Premio giovani ricercatori SISA 2001: Grant
del MIUR (Ministero Istruzione Università e Ricerca) per il progetto: "In vitro studies on the
inflammatory response induced by post-prandial lipoproteins in endothelial cells"
2000: Premio SISA
2000: Finalista per il Young Award Investigator al XII International Symposium on Atherosclerosis, Stoccolma
1999: Premio giovani ricervatori SISA.
1997: Premio SISA (Società Italiana Studio Aterosclerosi)
1997: Finalista per il Young Award Investigator all’XI International Symposium on Atherosclerosis, Parigi
Dati personali Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 (Codice in materia di protezione dei dati personali) e sue successive modifiche e integrazioni, nonché del Regolamento UE 679/2016 (Regolamento Generale sulla Protezione dei dati o, più brevemente, RGPD).
Autorizzo, ai sensi del D. Lgs 14/03/2013 n.33 (Riordino della disciplina riguardante gli obblighi di pubblicita', trasparenza e diffusione di informazioni da parte delle pubbliche amministrazioni), la pubblicazione di questo curriculum sul sito web dell’Università degli Studi di Milano nella sezione “Amministrazione trasparente”, “Consulenti e Collaboratori”.
ESPERIENZA PROFESSIONALE
Dal 2018 ad oggi Professore Ordinario di Farmacologia
Dipartimento di Scienze Farmacologiche e Biomolecolari, Facoltà di Scienze del Farmaco, Via Balzaretti 9, Milano, www.unimi.it
Insegnamenti collegatati al settore disciplinare 05/G1 Farmacologia BIO-14 nei corsi si Laurea di Farmacia e Biotecnologie del Farmaco, Facoltà di scienze del Farmaco e nel corso di Laurea di Scienze Biologiche, Facoltà di Scienze e Tecnologie
Dal 2016 al 2018 Adjunct Professor
School of Biomedical Sciences, Curtin Health Innovation Research Institute, Curtin University, Perth, Western Australia
Dal 2014 al 2018 Professore Associato di Farmacologia
Dipartimento di Scienze Farmacologiche e Biomolecolari, Facoltà di Scienze del Farmaco, Via Balzaretti 9, Milano, www.unimi.it
▪ Insegnamento di discipline correlate alla Farmacologia e Tossicologia agli studenti dei Corsi di Laurea delle Facoltà di Scienze del Farmaco e Scienze Biologiche
Settore disciplinare 05/G1 Farmacologia BIO-14
Dal 2012 al 2015 Honorary Senior Lecturer
The Blizard Institute, Barts and The London, School of Medicine & Dentistry Queen Mary University, Londra, Regno Unito
Dal 2008 al 2014 Ricercatore Universitario
Dipartimento di Scienze Farmacologiche e Biomolecolari, Facoltà di Scienze del Farmaco, Via Balzaretti 9, Milano, www.unimi.it
▪ Insegnamento di discipline correlate alla Farmacologia agli studenti dei Corsi di Laurea della Facoltà di Scienze del Farmaco
Settore disciplinare 05/G1 Farmacologia BIO-14
Dal 2002 al 2008 Assegnista di Ricerca
Dipartimento di Scienze Farmacologiche e Biomolecolari, Facoltà di Farmacia, Via Balzaretti 9, Milano, www.unimi.it
▪ Ricerca di base ed applicata in campo cardiovascolare
ISTRUZIONE E FORMAZIONE
Dal 2005 a oggi Responsabile del Laboratorio di Genetica Molecolare e Genomica Cardiovascolare
Centro per lo Studio dell’Aterosclerosi, Ospedale E. Bassini, Cinisello Balsamo, Milano
▪ Organizzazione pianificazione della ricerca in ambito cardiovascolare
Dal 2002 al 2004 Visiting Scientist
Atherosclerosis Research Unit, Karolinska Hospital, Karolinska Institute, Stoccolma, Svezia
▪ Ricerca in campo genetico e di genomica cardiovascolare
2003 Laurea in Biotecnologie Farmaceutiche (Seconda Laurea) Votazione 110/110 e lode
Dipartimento di Scienze Farmacologiche, Facoltà di Farmacia, via Balzaretti 9, Milano
Università degli Studi di Milano
▪ Biotecnologie Applicate alla Ricerca Biomedica
2002 Scuola di Specialità in Farmacologia
Votazione 70/70 e lode
Dipartimento di Scienze Farmacologiche, Facoltà di Farmacia, via Balzaretti 9, Milano
Università degli Studi di Milano
▪ Ricerca di base ed applicata in campo cardiovascolare
Dal 1998 al 2001 Dottorato di Ricerca (PhD)
Medicina Sperimentale: Aterosclerosi
Università degli Studi di Siena
1996 Laurea in Farmacia
Votazione 110/110 e lode
Dipartimento di Scienze Farmacologiche, Facoltà di Farmacia, via Balzaretti 9, Milano
Università degli Studi di Milano
▪ Discipline Farmaceutiche
COMPETENZE PERSONALI
Lingua madre Italiano
Altre lingue COMPRENSIONE PARLATO PRODUZIONE SCRITTA
Ascolto Lettura Interazione Produzione orale
Inglese C1 C1 C1 C1 C1
Competenze organizzative e gestionali ▪ Leadership (attualmente responsabile di un team di 10 persone)
ATTIVITA’ PROFESSIONALI
Progetti e Finanziamenti
2019-2022 PRIN: PROGETTI DI RICERCA DI RILEVANTE INTERESSE NAZIONALE
Bando 2017 (Prot. 2017K55HLC)
“Integrating metabolism and immunity: cellular and molecular pathways leading to metabolic dysregulation and autoimmunity”
Coordinatore di Unità
2019-2022 Fondazione Telethon GGP19146
“Exploiting regulatory T-cell metabolic reprogramming and vascular tropism as therapeutic tools for Familial Hypercholesterolemia”
Coordinatore del Progetto
2019-2020 EFSD/Lilly European Diabetes Research Programme; Bando Internazionale
“Metabolic rewiring of diabetic heart: unveiling the role of lipoproteins on cardiac function”
Coordinatore del Progetto
2018-2020 PCSK9 Competitive Grant Program, Amgen
“PCSK9 and cardiac function: bridging cellular lipid metabolism to mithocondrial function and heart failure”
Coordinatore del Progetto
2018-2020 ASGR1 Cardiovascular Grant, 3268293 Amgen; Bando Internazionale
“Unveiling the impact of ASGR1 deficiency on the immunoinflammatory signature during atherogenesis”
Coordinatore del Progetto
2017-2020 Fondazione Cariplo, Bando Ricerca Scientifica, 2016-0852, Bando Nazionale
“Proprotein convertase subtilisin/kexin type 9 (PCSK9): a link between lipotoxicity, mitochondrial dysfunction, and frailty-associated heart failure”
Coordinatore del Progetto
2017-2020 Aspire Cardiovascular Grant, WI218287, Bando Internazionale
“Unveiling the role of PCSK9 in heart physiology: focus on fatty acid metabolism, mitochondrial function and lipotoxicity”
Coordinatore del Progetto
2016-2020 Società Italiana Terapia Clinica e Sperimentale, STCS15-Mi-02, Bando Nazionale
“Role of PCSK9 in the post-prandial response: genetic and molecular aspects”
Coordinatore del Progetto
2017-2019 Fondazione Italiana per il Tuo Cuore, Centro Studi ANMCO, 470/15/HCF, Bando Nazionale
“HDL quality vs quantity in coronary artery disease”
Coordinatore del Progetto
2014-2018 Ministero della Salute, Bando Ricerca Finalizzata 2011-12, WFR GR-2011-02346974, Bando Nazionale
“Targeting inflammation in atherosclerosis: role and therapeutic potential of sphingosine 1-phosphate (S1P) and its receptors”
Responsabile di Unità
2013-2017 Fondazione Telethon GGP13002, Bando Nazionale
“Engineered T regulatory cells to control the immune-inflammatory response and the accelerated onset of atherosclerosis in familial hypercholesterolemia”
Coordinatore del Progetto
2012-2014 EU, COST Action BM0904_HDLnet, Bando Internazionale
“HDL: From Biological Understanding to Clinical Exploitation”
Responsabile di Unità
2011-2013 Fondazione Cariplo, Bando Ricerca Scientifica, 2010-0768, Bando Nazionale
“Role of Micro RNAs 143 and 145 in cardiovascular physiology and disease: from bench to bedside”
Responsabile di Unità
Competenze professionali Revisore per le seguenti Riviste Scientifiche
Acta Biochimica et Biophysica Sinica
Acta Diabetologica
Aging Health
American Journal of Pathology
American Journal of Physiology: Endocrinology and Metabolism
American Journal of Human Biology
Annals of Medicine
Arteriosclerosis Thrombosis Vascular Biology
Atherosclerosis
Biochemical Pharmacology
Biochimica et Byophisica Acta
Biomarkers
British Journal of Haematology
Cardiovascular Research
Cell Proliferation
Clinica Chimica Acta
Clinical Chemistry and Laboratory Medicine
Clinical Journal of American Society of Nephrology
Clinical Endocrinology
Clinical and Experimental Medicine
Clinical Nutrition
Cytokine
Diabetes Research and Clinical Practice
Diabetologia
Expert Review of Cardiovascular Therapy
European Heart Journal
European Heart Journal Preventive Cardiology
European Journal of Endocrinology
European Journal of Lipid Science and Technology
European Journal of Pharmacology
FEBS letter
Future Cardiology
Heart and Vessels
Hypertension
Human Immunology
International Journal of Obesity
Journal of Atherosclerosis and Thrombosis
Journal of the American College of Nutrition
Journal of Biological Regulators
Journal of Diabetes and Its Complications
Journal of Endocrinology
Journal of Internal Medicine
Journal of Leukocyte Biology
La Caixa
Life Sciences
Maturitas
Mediators of Inflammation
Medical Science Monitoring
Metabolism
Nutrition Metabolism and Cardiovascular Disease
Obesity
Pharmaceutical Biology
Pharmacological Research
Stroke
Thrombosis and Haemostasis
The Scandinavian Journal of Clinical & Laboratory Investigation
The Scandinavian Journal of Rheumatology
Tohoku Journal of Experimental Medicine
Toxicology Letters
Vascular Health and Risk Management
Associate Editor per le seguenti Riviste Scientifiche:
Annals of Medicine
Atherosclerosis
Cardiovascular Research
Giornale Italiano dell'Arteriosclerosi
Nutrition Metabolism and Cardiovascular Diseases
Public Library of Science (PLoS) One
Cariche Professionali e Accademiche ▪ Coordinatore del corso di dottorato di ricerca in Scienze farmacologiche biomolecolari, sperimentali e cliniche, 2020-2023.
▪ Vice Presidente SISA Lombardia, ad oggi.
▪ Section Editor della Rivista Scientifica Annals of Medicine
▪ Membro Advisory Board del National Institute of Rheumatic
▪ Tesoriere del gruppo ATVB dell’ESC “European Society of Cardiology”
▪ Delegato tavolo di Lavoro Patologie Diabetiche della Federazione Italiana Scienze Mediche (FISM), rappresentane della Società Italiana di Farmacologia 2019 ad oggi.
▪ Componente ESC Working Group on Atherosclerosis & Vascular Biology, Società Europea di Cardiologia (ESC). 2018 ad oggi.
▪ Membro del Comitato scientifico del Congresso Nazionale SIF 2020-2022
▪ Membro della Società Italiana di Farmacologia (SIF)-farmaindustria, ad oggi.
▪ Componente del Scientific Programme Committee e del Congress Committee, Società Europea per lo Studio dell’Aterosclerosi (EAS)
▪ Comitato Coordinatore “Giovani SISA” (fino al 2016), membro del Direttivo SISA Lombardia (dal 2015), Società Italiana per lo Studio dell’Aterosclerosi (SISA).
▪ Membro dell’ Associazione Europea per lo Studio del Diabete (EASD)
▪ Membro del Comitato Organizzatore e Scientifico dei seguenti Congressi:
• 89th Congress of the European Atherosclerosis Society, Helsinki 2021.
• 88th Congress of the European Atherosclerosis Society, Geneva 2020.
• 87th Congress of the European Atherosclerosis Society, Maastricht 2019.
• 86th Congress of the European Atherosclerosis Society, Lisbona 2018.
• 85th European Atherosclerosis Society meeting, Prague 2017. Scientific Committee
• 39th European Lipoprotein Club Meeting, Tutzing, Germany 2016.
• 84th European Atherosclerosis Society meeting, Innsbruck 2016. Congress Committee
• 83rd European Atherosclerosis Society meeting, Glasgow 2015. Poster Coordinator and Young Investigators chairs.
• 38th European Lipoprotein Club Meeting, Tutzing, Germany 2015.
• 82nd European Atherosclerosis Society meeting, Madrid 2014. Poster Coordinator.
• 37th European Lipoprotein Club Meeting, Tutzing, Germany 2014.
• 81st European Atherosclerosis Society meeting, Lyon 2013. Poster Award Committee.
• 36th European Lipoprotein Club Meeting, Tutzing, Germany 2013
• 80th European Atherosclerosis Society meeting, Milan 2012.
• 35th European Lipoprotein Club Meeting, Tutzing, Germany 2012
• XV International Symposium on Drugs Affecting Lipid Metabolism. Venice 2004
• Second International Meeting on PPARs: from Basic Science to Clinical Applications, Florence 2003
• 6th International Meeting on global risk assessment in cardiovascular disease and stroke. Florence 2002
• First International Meeting on PPARs: from Basic Science to Clinical Applications. Florence 2001
▪ Revisore di Richieste di Finanziamento per le seguenti Istituzioni di Ricerca:
• Dutch Research Council NWO
• Netherlands, Canada
• Dutch Heart Foundation, The Netherlands
• ERC Starting Grant, Brussels
• FWF Austrian Science Fund, Austria
• Medical Research Council, Regno Unito
• Ministero Italiano dell’Università e della Ricerca (MIUR), Italia
• Agence Nationale de la Recherche, Francia
• Dutch Diabetes Research Foundation, Paesi Bassi
• South African Medical Research Council, Sud Africa
• Conacuore Onlus, PRICARD grants, Italia
• Research Foundation Flanders (FWO), Belgio
• European Project RBUCE-UP, Francia
• Diabetes UK, Regno Unito
▪ Membro della Commissione Giudicatrice Esame finale Dottorato di Ricerca in Scienze del Farmaco, Università di Parma.
▪ Componente della Commissione Programma Erasmus Università degli Studi di Milano
▪ Componente della Commissione Paritetica del Corso di Laurea di Biotecnologie del Farmaco. Facoltà di Scienze del Farmaco.
▪ Componente di Commissioni per il conferimento di Borse Giovani Promettenti e per il conferimento ed il rinnovo di Assegni di Ricerca per il Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano.
▪ Componente della Commissione di vigilanza degli Esami di Stato per l’abilitazione all’esercizio della Professione di Farmacista.
▪ Componente del Collegio dei Docenti del Dottorato di Ricerca in Scienze Farmacologiche Sperimentali e Cliniche, Università degli Studi di Milano.
▪ Valutatore delle tesi di Dottorato dell’Università degli Studi di Roma la Sapienza.
▪ Componente del Comitato Etico (Farmacologo) degli Istituti Clinici di Perfezionamento.
ULTERIORI INFORMAZIONI
Pubblicazioni
Totale
Public. Public. con IF IF totale IF medio Total citaz Scopus H-index
208
173
1168,311 6,753 7165 48
1. Genetically determined hypercholesterolaemia results into premature leucocyte telomere length shortening and reduced haematopoietic precursors. Baragetti A, Bonacina F, Da Dalt L, Moregola A, Zampoleri V, Pellegatta F, Grigore L, Pirillo A, Spina R, Cefalù AB, Averna M, Norata GD , Catapano AL. Eur J Prev Cardiol. 2020 Nov 17:zwaa115. doi: 10.1093/eurjpc/zwaa115. Online ahead of print.PMID: 33624064
IF 5.864
2. Novel acquisitions in cell immunometabolism. Norata GD , Matarese G.
Mol Aspects Med. 2021 Feb;77:100945. doi: 10.1016/j.mam.2021.100945. Epub 2021 Feb 5.PMID: 33551237 IF 9.577
3. Gut microbiota functional dysbiosis relates to individual diet in subclinical carotid atherosclerosis. Baragetti, A., Severgnini, M., Olmastroni, E., ... Norata GD , Catapano, A.L., Peano, C. Nutrients, 2021 Jan 21;13(2):304. doi: 10.3390/nu13020304. PMID: 33494335 IF 4.546
4. Worldwide Changes in Total Cholesterol and Non-HDL-Cholesterol Trends Indicate Where the Challenges Are for the Coming Years. Pirillo A, Norata GD, Catapano AL. Clin Chem. 2021 Jan 8;67(1):30-32. doi: 10.1093/clinchem/hvaa246.PMID: 33236047
IF 7.292
5. Insights from ORION studies: focus on inclisiran safety. Catapano AL, Pirillo A, Norata GD. Cardiovasc Res. 2021 Jan 1;117(1):24-26. doi: 10.1093/cvr/cvaa139. IF 8.168
6. Endothelial Function in cardiovascular prevision medicine: a position paper on behalf of the European Society of Cardiology. Alexander Y, Osto E, Schmidt-Trucksäss A, Shechter M, Trifunovic D, Duncker DJ, Aboyans V, Bäck M, Badimon L, Cosentino F, De Carlo M, Dorobantu M, Harrison DG, Guzik TJ, Hoefer I, Morris PD, Norata GD, Suades R, Taddei S, Vilahur G, Waltenberger J, Weber C, Wilkinson F, Bochaton-Piallat ML, Evans PC. Cardiovasc Res. 2021 Jan 1;117(1):29-42. doi: 10.1093/cvr/cvaa085. IF 8.168
7. Low Plasma Lecithin: Cholesterol Acyltransferase (LCAT) Concentration Predicts Chronic Kidney Disease. Baragetti A, Ossoli A, Strazzella A, Simonelli S, Baragetti I, Grigore L, Pellegatta F, Catapano AL, Norata GD, Calabresi L.J Clin Med. 2020 Jul 18;9(7):2289. doi: 10.3390/jcm9072289.PMID: 32708515 IF 1.883
8. Caloric Restriction Promotes Immunometabolic Reprogramming Leading to Protection from Tuberculosis. Palma C, La Rocca C, Gigantino V, Aquino G, Piccaro G, Di Silvestre D, Brambilla F, Rossi R, Bonacina F, Lepore MT, Audano M, Mitro N, Botti G, Bruzzaniti S, Fusco C, Procaccini C, De Rosa V, Galgani M, Alviggi C, Puca A, Grassi F, Rezzonico-Jost T, Norata GD, Mauri P, Netea MG, de Candia P, Matarese G. Cell Metab. 2021 Jan 4:S1550-4131(20)30671-9. doi: 10.1016/j.cmet.2020.12.016. Cell Metabolism, 2021 Feb 2;33(2):300-318.e12. doi: 10.1016/j.cmet.2020.12.016.
Epub 2021 Jan 8. PMID: 33421383 IF 21.567
9. Adoptive transfer of CX3CR1 transduced-T regulatory cells improves homing to the atherosclerotic plaques and dampens atherosclerosis progression. Bonacina F, Martini E, Svecla M, Nour J, Cremonesi M, Beretta G, Moregola A, Pellegatta F, Zampoleri V, Catapano AL, Kallikourdis M, Norata GD. Cardiovasc Res. 2020 Sep 15:cvaa264. doi: 10.1093/cvr/cvaa264. Online ahead of print.PMID: 32931583 IF 8.168
10. Metabolic adaptations of cells at the vascular-immune interface during atherosclerosis.
Bonacina F, Da Dalt L, Catapano AL, Norata GD. Mol Aspects Med. 2020 Oct 5:100918. doi: 10.1016/j.mam.2020.100918. Online ahead of print.PMID: 33032828
IF 9.577
11. Dyslipidemia and regulatory T cell migration: an immunometabolic connection?
Binder C, Norata GD. Cardiovasc Res. 2020 Sep 17:cvaa269. doi: 10.1093/cvr/cvaa269. Online ahead of print.PMID: 32941603 IF 8.168
12. Omega n-3 Supplementation: Exploring the Cardiovascular Benefits Beyond Lipoprotein Reduction. Zambon A, Pirillo A, Zambon S, Norata GD, Catapano AL. Curr Atheroscler Rep. 2020 Oct 3;22(12):74. doi: 10.1007/s11883-020-00893-1.PMID: 33009961 IF 4.608
11. Recent insights into low-density lipoprotein metabolism and therapy. Angela Pirillo, Alberico Catapano, and Norata GD. Curr Opin Clin Nutr Metab Care. 2021 Mar 1;24(2):120-126. doi: 10.1097/MCO.0000000000000727.PMID: 33394716 IF 3.775
13. Epidemiology of dyslipidaemias Angela Pirillo, Manuela Casula, Elena Olmastroni, Norata GD, and Alberico Catapano. Nature Reviews Cardiology. 2020 [Epub ahead of print] IF 20.260
14. Impact of protein glycosylation on lipoprotein metabolism and atheroslcerosis. Norata GD Cardiovasc Res.[Epub ahead of print] IF 8.168
15. P2X7 receptor activity limits accumulation of T cells within tumors.
Fabio Grassi, Andrea Romagnani, Elsa Rottoli, Emilia Maria Cristina Mazza, Tanja Rezzonico-Jost, Benedetta De Ponte Conti, Michele Proietti, Michela Perotti, Elisa Civanelli, Lisa Perruzza, Alberico L. Catapano, Andrea Baragetti, Elena Tenedini, Enrico Tagliafico, Simonetta Falzoni, Francesco Di Virgilio, Norata GD , and Silvio Bicciato. Cancer Research 2020 Jul 22;canres.3807.2019. doi: 10.1158/0008-5472.CAN-19-3807. Online ahead of print. IF 9.727
16. New pharmacological approaches to target PCSK9. Catapano AL, Pirillo A, Norata GD. Current Atherosclerosis Reports. 2020 Jun 3;22(7):24. doi: 10.1007/s11883-020-00847-7 IF 4.608
17. LDL-Cholesterol-Lowering Therapy. Pirillo A, Norata GD, Catapano AL.
Handb Exp Pharmacol. 2020 Apr 30. doi: 10.1007/164_2020_361
18. Efficacy and Safety of Volanesorsen (ISIS 304801): the Evidence from Phase 2 and 3 Clinical Trials. Fogacci F, Norata GD, Peter P. Toth, Arca M., Cicero A.F. G
Current Atherosclerosis Reports doi: 10.1007/s11883-020-00836-w IF 4.608
19. Beyond LDL-C levels, does remnant cholesterol estimation matter? Pirillo A, Norata GD, Catapano AL.
Eur J Prev Cardiol. 2020 Feb 3:2047487319899622. doi: 10.1177/2047487319899622. [Epub ahead of print]. IF 5.864
20. Progression of conventional cardiovascular risk factors and vascular disease risk in individuals: insights from the PROG-IMT consortium. Bahls M, Lorenz MW, Dörr M, Gao L, Kitagawa K, Tuomainen TP, Agewall S, Berenson G, Catapano AL, Norata GD, Bots ML, van Gilst W, Asselbergs FW, Brouwers FP, Uthoff H, Sander D, Poppert H, Hecht Olsen M, Empana JP, Schminke U, Baldassarre D, Veglia F, Franco OH, Kavousi M, de Groot E, Mathiesen EB, Grigore L, Polak JF, Rundek T, Stehouwer CD, Skilton MR, Hatzitolios AI, Savopoulos C, Ntaios G, Plichart M, McLachlan S, Lind L, Willeit P, Steinmetz H, Desvarieux M, Ikram MA, Johnsen SH, Schmidt C, Willeit J, Ducimetiere P, Price JF, Bergström G, Kauhanen J, Kiechl S, Sitzer M, Bickel H, Sacco RL, Hofman A, Völzke H, Thompson SG; PROG-IMT Study Group. Eur J Prev Cardiol. 2019 Oct 16:2047487319877078. doi: 10.1177/2047487319877078 IF 5.864
21. Cholesterol membrane content has a ubiquitous evolutionary function in immune cell activation: the role of HDL. Bonacina F, Pirillo A, Catapano AL, Norata GD. Curr Opin Lipidol. 2019 Oct ;30(6):462-469. IF 4.254
22. Lipid accumulation impairs lysosomal acid lipase activity in hepatocytes: Evidence in NAFLD patients and cell cultures. Gomaraschi M, Fracanzani AL, Dongiovanni P, Pavanello C, Giorgio E, Da Dalt L, Norata GD, Calabresi L, Consonni D, Lombardi R, Branchi A, Fargion S. Biochim Biophys Acta Mol Cell Biol Lipids. 2019 Sep 7;1864(12):158523. IF 4.519
23. Acido Bempedoico: dalla Farmacologia alla Clinica. Pirillo A, Catapano AL, Norata GD. Giornale Italiano dell’Arteriosclerosi. 2019;10(3):40-49.
24. Hormonal control of trained immunity: aldosterone at the crossroad between activation of innate immunity and cardiovascular diseases. Matarese G, Norata GD. Cardiovasc Res. 2019 2020 Feb 1;116(2):256-257. IF 8.168
25. Single systemic transfer of a human gene associated with exceptional longevity halts the progression of atherosclerosis and inflammation in ApoE knockout mice through a CXCR4-mediated mechanism. Puca AA, Carrizzo A, Spinelli C, Damato A, Ambrosio M, Villa F, Ferrario A, Maciag A, Fornai F, Lenzi P, Valenti V, di Nonno F, Accarino G, Madonna M, Forte M, Calì G, Baragetti A, Norata GD, Catapano AL, Cattaneo M, Izzo R, Trimarco V, Montella F, Versaci F, Auricchio A, Frati G, Sciarretta S, Madeddu P, Ciaglia E, Vecchione C. Eur Heart J. 2019 Jul 10. pii: ehz459. doi: 10.1093/eurheartj/ehz459. IF 22.673
26. Fuel for thought: Immunometabolism is a paradigm shift in understanding immunity in cardiovascular disease. Caligiuri G, Norata GD. Cardiovasc Res. 2019;115(9):1383-1384. IF 8.168
27. Immunometabolic function of cholesterol in cardiovascular disease and beyond. Yvan-Charvet L, Bonacina F, Guinamard RR, Norata GD. Cardiovasc Res. 2019;115(9):1393-1407. IF 8.168
28. The role of monocytes and macrophages in human atherosclerosis, plaque neoangiogenesis and atherothrombosis. Moroni F, Ammirati E, Norata GD, Magnoni M, Camici PG. Mediators Inflamm. 2019:7434376. IF 3.758
29. Cholesterol metabolism, pancreatic β-cell function and diabetes. Perego C, Da Dalt L, Pirillo A, Galli A, Catapano AL, Norata GD. Biochim Biophys Acta Mol Basis Dis. 2019;1865(9):2149-2156. IF 4.519
30. Identification of AnnexinA1 as an endogenous regulator of RhoA, and its role in the pathophysiology and experimental therapy of type 2 diabetes. Purvis GSD, Collino M, Loiola RA, Baragetti A, Chiazza F, Brovelli M, Sheikh MH, Collotta D, Cento A, Mastrocola R, Aragno M, Cutrin JC, Reutelingsperger C, Grigore L, Catapano AL, Yaqoob MM, Norata GD, Solito E, Thiemermann C. Front Immunol. 2019;10:571.
IF 5.085
31. The Interconnection Between Immuno-Metabolism, Diabetes, and CKD. Bonacina F, Baragetti A, Catapano AL, Norata GD. Curr Diab Rep. 2019 Mar 19;19(5):21. IF 3.686
32. Pentraxin 3 deficiency protects from the metabolic inflammation associated to diet-induced obesity. Bonacina F, Moregola A, Porte R, Baragetti A, Bonavita E, Salatin A, Grigore L, Pellegatta F, Molgora M, Sironi M, Barbati E, Mantovani A, Bottazzi B, Catapano AL, Garlanda C, Norata GD. Cardiovasc Res. 2019 Nov 1;115(13):1861-1872.
IF 8.168
33. Lysosomal Acid Lipase: From Cellular Lipid Handler to Immunometabolic Target. Gomaraschi M, Bonacina F, Norata GD. Trends Pharmacol Sci. 2019;40(2):104-115.
IF 13.503
34. Novel strategies to target proprotein convertase subtilisin kexin 9: beyond monoclonal antibodies. Seidah NG, Prat A, Pirillo A, Catapano AL, Norata GD. Cardiovasc Res. 2019 Mar 1;115(3):510-518. IF 8.168
35. Impact of Cardiovascular Risk Factors and Pharmacologic Treatments on Carotid Intraplaque Neovascularization Detected by Contrast-Enhanced Ultrasound. Magnoni M, Ammirati E, Moroni F, Norata GD, Camici PG. J Am Soc Echocardiogr. 2019;32(1):113-120. IF 5.508
36. High-density lipoprotein cholesterol levels, cardiovascular disease risk and cancer: a relation which does not apply to all? Catapano AL, Pirillo A, Norata GD. Cardiovasc Res. 2019;115(1):6-7. IF 8.168
37. Biological consequences of dysfunctional HDL. Pirillo A, Catapano AL, Norata GD. Curr Med Chem. 2019;26(9):1644-1664. IF 4.184
38. PCSK9 deficiency reduces insulin secretion and promotes glucose intolerance: the role of the LDL receptor. Da Dalt L, Ruscica M, Bonacina F, Balzarotti G, Dhyani A, Di Cairano E, Baragetti A, Arnaboldi L, De Metrio S, Pellegatta F, Grigore L, Botta M, Macchi C, Uboldi P, Perego C, Catapano AL, Norata GD. Eur Heart J. 2019; 40(4):357-368. IF 22.673
39. Applicazioni traslazionali dell'immunometabolismo nelle malattie metaboliche e nel diabete. Bonacina F, Baragetti A, Catapano AL, Norata GD. Il Diabete, 2018; 30(3):216-225.
40. Gene silencing strategies in the treatment of dyslipidemias. Pirillo A, Catapano AL, Norata GD. Giornale Italiano dell’Arteriosclerosi, 2018; 9(2):34-46.
41. Myeloid Apolipoprotein E controls Dendritic Cell antigen presentation function and adaptive immunity. Bonacina F, Coe D, Wang G, Longhi MP, Baragetti A, Moregola A, Garlaschelli K, Uboldi P, Pellegatta F, Grigore L, Da Dalt L, Annoni A, Gregori S, Xiao Q, Caruso D, Mitro N, Catapano AL, Marelli-Berg FM, Norata GD. Nat Commun. 2018; 9(1):3083. IF 11.878
42. Cluster-assembled zirconia substrates promote long term differentiation and functioning of human islets of Langerhans. Galli A, Maffioli E, Sogne E, Moretti S, di Cairano ES, Negri A, Nonnis S, Norata GD, Bonacina F, Borghi F, Podesta A, Bertuzzi F, Milani P, Lenardi C, Tedeschi G, Perego C. Sci Rep. 2018;8(1):9979.
IF 4.011
43. Fatty acid metabolism complements glycolysis in the selective regulatory T cell expansion during tumor growth. Pacella I, Procaccini C, Focaccetti C, Miacci S, Timperi E, Faicchia D, Severa M, Rizzo F, Coccia EM, Bonacina F, Mitro N, Norata GD, Rossetti G, Ranzani V, Pagani M, Giorda E, Wei Y, Matarese G, Barnaba V, Piconese S. Proc Natl Acad Sci. 2018;115(28):E6546-E6555. IF 9.580
44. Trained immunity and cardiovascular disease: is it time for translation to humans? Norata GD. Cardiovasc Res. 2018;114(6):e41-e42. IF 7.014
45. Proprotein Convertase Subtilisin-Kexin type-9 (PCSK9) and triglyceride-rich lipoprotein metabolism: Facts and gaps. Baragetti A, Grejtakova D, Casula M, Olmastroni E, Jotti GS, Norata GD, Catapano AL, Bellosta S. Pharmacol Res. 2018;130:1-11. IF 5.574
46. The Interplay of Lipids, Lipoproteins, and Immunity in Atherosclerosis. Pirillo A, Bonacina F, Norata GD, Catapano AL. Curr Atheroscler Rep. 2018;20(3):12. IF 3.769
47. Predictive value for cardiovascular events of common carotid intima media thickness and its rate of change in individuals at high cardiovascular risk - Results from the PROG-IMT collaboration. Lorenz MW, Gao L, Ziegelbauer K, Norata GD, Empana JP, Schmidtmann I, Lin HJ, McLachlan S, Bokemark L, Ronkainen K, Amato M, Schminke U, Srinivasan SR, Lind L, Okazaki S, Stehouwer CDA, Willeit P, Polak JF, Steinmetz H, Sander D, Poppert H, Desvarieux M, Ikram MA, Johnsen SH, Staub D, Sirtori CR, Iglseder B, Beloqui O, Engström G, Friera A, Rozza F, Xie W, Parraga G, Grigore L, Plichart M, Blankenberg S, Su TC, Schmidt C, Tuomainen TP, Veglia F, Völzke H, Nijpels G, Willeit J, Sacco RL, Franco OH, Uthoff H, Hedblad B, Suarez C, Izzo R, Zhao D, Wannarong T, Catapano A, Ducimetiere P, Espinola-Klein C, Chien KL, Price JF, Bergström G, Kauhanen J, Tremoli E, Dörr M, Berenson G, Kitagawa K, Dekker JM, Kiechl S, Sitzer M, Bickel H, Rundek T, Hofman A, Mathiesen EB, Castelnuovo S, Landecho MF, Rosvall M, Gabriel R, de Luca N, Liu J, Baldassarre D, Kavousi M, de Groot E, Bots ML, Yanez DN, Thompson SG; PROG-IMT study group. PLoS One 2018;13(4):e0191172. IF 2.776
48. Zc3h10 is a novel mitochondrial regulator. Audano M, Pedretti S, Cermenati G, Brioschi E, Diaferia G, Ghisletti S, Cuomo A, Bonaldi T, Salerno F, Mora M, Grigore L, Garlaschelli K, Baragetti A, Bonacina F, Catapano AL, Norata GD, Crestani M, Caruso D, Saez E, De Fabiani E, Mitro N. EMBO Rep. 2018;19(4). IF 8.383
49. Regulatory T Cell Migration Is Dependent on Glucokinase-Mediated Glycolysis. Kishore M, Cheung KCP, Fu H, Bonacina F, Wang G, Coe D, Ward EJ, Colamatteo A, Jangani M, Baragetti A, Matarese G, Smith DM, Haas R, Mauro C, Wraith DC, Okkenhaug K, Catapano AL, De Rosa V, Norata GD, Marelli-Berg FM. Immunity. 2017;47(5):875-889. IF 19.734
50. Disease trends over time and CD4+CCR5+ T-cells expansion predict carotid atherosclerosis development in patients with systemic lupus erythematosus. Baragetti A, Ramirez GA, Magnoni M, Garlaschelli K, Grigore L, Berteotti M, Scotti I, Bozzolo E, Berti A, Camici PG, Catapano AL, Manfredi AA, Ammirati E, Norata GD. Nutr Metab Cardiovasc Dis. 2018;28(1):53-63. IF 3.340
51. Targeting cholesterol in non-ischemic heart failure: a role for LDLR gene therapy? Catapano AL, Pirillo A, Norata GD. Mol Ther. 2017;25(11):2435-2437. IF 7.008
52. Strategies for the use of Non-Statin therapies. PirilloA, Norata GD, Catapano AL. Curr Opin Lipidol. 2017;28(6):458-464. IF 3.853
53. Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and prospectives. Catapano AL, Pirillo A, Norata GD. Vasc Health Risk Manag 2017;13:343-351.
54. PCSK9 deficiency results in increased ectopic fat accumulation in experimental models and in humans. Baragetti A, Balzarotti G, Grigore L, Pellegatta F, Guerrini U, Pisano G, Fracanzani AL, Fargion S, Norata GD, Catapano AL. Eur J Prev Cardiol. 2017;24(17):1870-1877. IF 4.542
55. Advances in Hypercholesterolemia. Pirillo A, Norata GD, Catapano AL. Medicinal Chemistry III vol. 7, pp. 663–93. Oxford: Elsevier
56. PCSK9 inhibition in statin-intolerant HeFH patients: What's new? Casula M, Pirillo A, Norata GD, Catapano AL. Eur J Prev Cardiol. 2017;24(14):1525-1527. IF 4.542
57. Arctigenin improves vascular tone and decreases inflammation in human saphenous vein. Daci A, Neziri B, Krasniqi S, Cavolli R, Alaj R, Norata GD, Beretta G. Eur J Pharmacol. 2017;810:51-56. IF 3.040
58. Automatic identification of variables in epidemiological datasets using logic regression. Lorenz MW, Abdi NA, Scheckenbach F, Pflug A, Bülbül A, Catapano AL, Agewall S, Ezhov M, Bots ML, Kiechl S, Orth A; PROG-IMT study group. BMC Med Inform Decis Mak. 2017;17(1):40.
59. Long pentraxin PTX3 as a prognostic marker of cardiovascular mortality in patients with chronic kidney disease. Baragetti A, Norata GD. Pol Arch Intern Med. 2017;127(3):152-153. IF 2.882
60. A past and present overview of macrophage metabolism and functional outcomes. Curi R, de Siqueira Mendes R, de Campos Crispin LA, Norata GD, Sampaio SC, Newsholme P. Clin Sci (Lond). 2017;131(12):1329-1342. IF 5.220
61. mTORC1 activity repression by late endosomal phosphatidylinositol 3,4-bisphosphate. Marat AL, Wallroth A, Lo WT, Müller R, Norata GD, Falasca M, Schultz C, Haucke V. Science. 2017;356(6341):968-972. IF 41.058
62. Vascular inflammation and low density lipoproteins: is cholesterol the link? A lesson from the clinical trials. Catapano AL, Pirillo A, Norata GD. Br J Pharmacol. 2017;174(22):3973-3985. IF 6.810
63. Translating the microRNA signature of microvesicles derived from human coronary artery smooth muscle cells in patients with familial hypercholesterolemia and coronary artery disease. De Gonzalo-Calvo D, Cenarro A, Garlaschelli K, Pellegatta F, Vilades D, Nasarre L, Camino-Lopez S, Crespo J, Carreras F, Leta R, Catapano AL, Norata GD, Civeira F, Llorente-Cortes V. J Mol Cell Cardiol 2017;106:55-67. IF 5.296
64. T follicular helper cells promote a beneficial gut ecosystem for host metabolic homeostasis by sensing microbiota derived extracellular ATP. Perruzza L, Gargari G, Proietti M, Fosso B, D’Erchia AM, Faliti CE, Rezzonico-Jost T, Scribano D, Mauri L, Colombo D, Pellegrini G, Moregola A, Mooser C, Pesole G, Nicoletti M, Norata GD, Geuking MB, McCoy KD, Guglielmetti S, Grassi F. Cell Rep. 2017;18(11):2566-2575.
IF 8.032
65. Obesity-induced metabolic stress leads to biased effector memory CD4+T cell differentiation via PI3K p110d/Akt-mediated signals. Mauro C, Smith J, Cucchi D, Coe D, Fu H, Bonacina F, Baragetti A, Cermenati G, Caruso D, Mitro N, Catapano AL, Ammirati E, Longhi MP, Okkenhaug K, Norata GD, Marelli-Berg FM. Cell Metab. 2017;25(3):593-609. IF 20.565
66. Translating the biology of adipokines in atherosclerosis and cardiovascular diseases: gaps and open questions. Ruscica M, Baragetti A, Catapano AL, Norata GD. Nutr Metab Cardiovasc Dis. 2017;27(5):379-395. IF 3.318
67. Circulating CD14+ and CD14highCD16- classical monocytes are reduced in patients with signs of plaque neovascularization in the carotid artery. Ammirati E, Moroni F, Magnoni M, Di Terlizzi S, Villa C, Sizzano F, Palini A, Garlaschelli K, Tripiciano F, Scotti I, Catapano AL, Manfredi AA, Norata GD, Camici PG. Atherosclerosis. 2016; 255:171-178. IF 4.239
68. Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering. Norata GD, Tavori H, Pirillo A, Fazio S, Catapano AL. Cardiovasc Res. 2016;112(1):429-442. IF 5.878
69. Genetically determined telomeres shortening is associated with carotid atherosclerosis progression and increased incidence of cardiovascular events. Baragetti A, Palmen J, Garlaschelli K, Grigore L, Humphries S, Talmud PJ, Catapano AL, Norata GD. Int J Cardiol. 2016;223:43-45. IF 6.189
70. Epicardial adipose tissue (EAT) thickness is associated with cardiovascular and liver damage in nonalcoholic fatty liver disease. Fracanzani AL, Pisano G, Baragetti A, Consonni D, Tiraboschi S, Bertelli C, Norata GD, Dongiovanni P, Valenti L, Grigore L, Tonella T, Catapano AL, Fargion S. PLoS One 2016;11(9):e0162473. IF 2.806
71. Vascular pentraxin 3 controls arterial thrombosis by targeting collagen and fibrinogen induced platelets aggregation. Bonacina F, Barbieri SS, Cutuli L, Amadio P, Doni A, Sironi M, Tartari S, Mantovani A, Bottazzi B, Garlanda C, Tremoli E, Catapano AL, Norata GD. Biochim Biophys Acta. 2016;1862(6):1182-1190. IF 5.476
72. Applicability of the 2013 ACC/AHA Risk Assessment and Cholesterol Treatment Guidelines in the Real World: Results from a Multiethnic Case-Control Study. Magnoni M, Berteotti M, Norata GD, Limite LR, Peretto G, Cristell N, Maseri A, Cianflone D. Ann Med. 2016;48(4):282-292. IF 3.715
73. Niemann-Pick C1-Like 1 (NPC1L1) inhibition and cardiovascular diseases. Pirillo A, Catapano AL, Norata GD. Curr Med Chem. 2016;23(10):983-999. IF 3.455
74. Progression of carotid vascular damage and cardiovascular events in non alcoholic fatty liver disease patients compared to the general population during 10 Years of follow-up. Fracanzani AL, Tiraboschi S, Pisano G, Consonni D, Baragetti A, Bertelli C, Norata GD, Valenti L, Grigore L, Porzio M, Catapano AL, Fargion S. Atherosclerosis 2016;246:208-213. IF 4.239
75. Normative values for carotid intima media thickness and its progression: Are they transferrable outside of their cohort of origin? Liao X, Norata GD, Polak JF, Stehouwer CD, Catapano A, Rundek T, Ezhov M, Sander D, Thompson SG, Lorenz MW; PROG-IMT study group. Eur J Prev Cardiol. 2016;23(11):1165-1173. IF 3.606
76. Subclinical atherosclerosis is associated with Epicardial Fat Thickness and hepatic steatosis in the general population. Baragetti A, Pisano G, Bertelli C, Garlaschelli K, Grigore L, Fracanzani AL, Fargion S, Norata GD, Catapano AL. Nutr Metab Cardiovasc Dis. 2016;26(2):141-153. IF 3.679
77. Longer genotypically-estimated leukocyte telomere length is associated with increased adult glioma risk. Walsh KM, Codd V, Rice T, Nelson CP, Smirnov IV, McCoy LS, Hansen HM, Elhauge E, Ojha J, Francis SS, Madsen NR, Bracci PM, Pico AR, Molinaro AM, Tihan T, Berger MS, Chang SM, Prados MD, Jenkins RB, Wiemels JL; ENGAGE Consortium Telomere Group, Samani NJ, Wiencke JK, Wrensch MR. Oncotarget. 2015 Dec 15;6(40):42468-42477. IF 5.008
78. Polymorphic Variants of SCN1A and EPHX1 Influence Plasma Carbamazepine Concentration, metabolism and pharmacoresistance in a population of kosovar albanian epileptic patients. Daci A, Beretta G, Vllasaliu D, Shala A, Govori V, Norata GD, Krasniqi S. PLoS One. 2015 Nov 10;10(11):e0142408. IF 3.057
79. The cellular and molecular basis of translational immunometabolism. Norata GD, Caligiuri G, Chavakis T, Matarese G, Netea MG, Nicoletti A, O'Neill LAJ, Marelli-Berg FM. Immunity. 2015;43(3):421-434. IF 24.082
80. Functional Analysis of a Carotid Intima-Media Thickness Locus Implicates BCAR1 and Suggests a Causal Variant. Boardman-Pretty F, Smith AJ, Cooper J, Palmen J, Folkersen L, Hamsten A, Catapano AL, Melander O, Price JF, Kumari M, Deanfield JE, Kivimäki M, Gertow K, Baragetti A, Norata GD, Humphries SE. Circ Cardiovasc Genet. 2015;8(5):696-706. IF 3.719
81. Apolipoprotein C-III: from pathophysiology to pharmacology. Norata GD, Tsimikas S, Pirillo A, Catapano AL. Trends Pharmacol Sci. 2015;36(10):675-687. IF 11.840
82. Carotid Intima Media Thickness progression and risk of vascular events in people with diabetes mellitus- results from the PROG-IMT collaboration. Lorenz MW, Price JF, Robertson C, Bots ML, Polak JF, Poppert H, Kavousi M, Dörr M, Stensland E, Ducimetiere P, Ronkainen K, Kiechl S, Sitzer M, Rundek T, Lind L, Liu J, Bergström G, Grigore L, Bokemark L, Friera A, Yanez D, Bickel H, Ikram MA, Völzke H, Johnsen SH, Empana JP, Tuomainen TP, Willeit P, Steinmetz H, Desvarieux M, Xie W, Schmidt C, Norata GD, Suarez C, Sander D, Hofman A, Schminke U, Mathiesen E, Plichart M, Kauhanen J, Willeit J, Sacco RL, McLachlan S, Zhao D, Fagerberg B, Catapano AL, Gabriel R, Franco OH, Bülbül A, Scheckenbach F, Pflug A, Gao L, Thompson SG. Diabetes Care 2015;38(10):1921-1929. IF 8.934
83. PI3K-C2γ 3 is a Rab5 effector selectively controlling endosomal Akt2 activation downstream insulin signaling. Braccini L, Ciraolo E, Campa CC, Perino A, Longo DL, Tibolla G, Pregnolato M, Cao Y, Tassone B, Damilano F, Laffargue M, Calautti E, Falasca M, Norata GD, Backer J, Hirsch E. Nat Commun. 2015;6:7400. IF 11.329
84. Peak inflammation in atherosclerosis, primary biliary cirrhosis and autoimmune arthritis is counter-intuitively associated with regulatory T cell enrichment. Garetto S, Trovato AE, Lleo A, Sala F, Martini E, Betz AG, Norata GD, Invernizzi P, Kallikourdis M. Immunobiology. 2015;220(8):1025-1029. IF 2.871
85. Markers of inflammation associated with plaque progression and instability in patients with carotid atherosclerotic. Ammirati E, Moroni F, Norata GD, Magnoni M, Camici PG. Mediators Inflamm. 2015;2015:718329. IF 3.418
86. An acidic microenvironment sets the humoral pattern recognition molecule PTX3 in a tissue repair mode. Doni A, Musso T, Morone D, Bastone A, Zambelli V, Sironi M, Castagnoli C, Cambieri I, Stravalaci M, Pasqualini F, Laface I, Valentino S, Tartari S, Ponzetta A, Maina V, Barbieri SS, Tremoli E, Catapano AL, Norata GD, Bottazzi B, Garlanda C, Mantovani A. J Exp Med. 2015;212(6):905-925. IF 11.240
87. IDOL N342S Variant, atherosclerosis progression and cardiovasculard disorders in the Italian general population. Dhyani A, Tibolla G, Baragetti A, Garlaschelli K, Pellegatta F, Grigore L, Norata GD, Catapano AL. PLoS One. 2015;10(4):e0122414.
IF 3.057
88. Fibronectin extra domain A stabilizes atherosclerotic plaque phenotype in apolipoprotein E and in LDL-receptor-deficient mice. Pulakazhi Venu VK, Uboldi P, Dhyani A, Patrini A, Baetta R, Nicola Ferri N, Corsini A, Andrés F. Muro F, Catapano AL, Norata GD. Thromb Haemost. 2015;114(1):186-197. IF 5.255
89. Homozygous familial hypobetalipoproteinemia: two novel mutations in the splicing sites of apolipoprotein B gene and review of the literature. Cefalù AB, Norata GD, Ghiglioni DG, Noto D, Uboldi P, Garlaschelli K, Baragetti A, Spina R, Valenti V, Pederiva C, Riva E, Terracciano L, Zoja A, Grigore L, Averna MR, Catapano AL. Atherosclerosis. 2015, 239(1):209-217. IF 3.942
90. HDL in Infectious Diseases and Sepsis. Pirillo A, Catapano AL, Norata GD. Handb Exp Pharmacol. 2015;224:483-508.
91. Impact of systemic inflammation and autoimmune diseases on apoA-I and HDL plasma levels and functions. Montecucco F, Favari E, Norata GD, Ronda N, Nofer J, Vuilleumier N. Handb Exp Pharmacol. 2015;224:455-482.
92. Inflammatory markers and extent and progression of early atherosclerosis: meta-analysis of individual-participant-data from 20 prospective studies of the PROG-IMT collaboration. Willeit P, Thompson SG, Agewall S, Bergström G, Bickel H, Catapano AL, Chien KL, de Groot E, Empana JP, Etgen T, Franco OH, Iglseder B, Johnsen SH, Kavousi M, Lind L, Liu J, Mathiesen EB, Norata GD, Olsen MH, Papagianni A, Poppert H, Price JF, Sacco RL, Yanez DN, Zhao D, Schminke U, Bülbül A, Polak JF, Sitzer M, Hofman A, Grigore L, Dörr M, Su TC, Ducimetière P, Xie W, Ronkainen K, Kiechl S, Rundek T, Robertson C, Fagerberg B, Bokemark L, Steinmetz H, Arfan Ikram M, Völzke H, Lin HJ, Plichart M, Tuomainen TP, Desvarieux M, McLachlan S, Schmidt C, Kauhanen J, Willeit J, Lorenz MW, Sander D; for the PROG-IMT study group. Eur J Prev Cardiol. 2016;23(2):194-205. IF 3.361
93. The arachidonic acid metabolome serves as a conserved regulator of cholesterol metabolism. Demetz E, Schroll A, Auer K, HeimC, Patsch JR, Eller P, Theurl M, Theurl I, Theurl M Seifert M, Lener D, Stanzl U, Haschka D, Asshoff M, Dichtl S, Nairz M, Huber E, Stadlinger M, Li X, Pallweber P, Scharnagl H, Stojakovic T, März W,. Kleber ME, Garlaschelli K, Uboldi P, Catapano AL, Stellaard F, Rudling M, Kuba K, Imai Y, Arita M, Pramstaller PP, Tietge UJF, Trauner M, Norata GD, Claudel T, Hicks AA, Weiss G, Tancevski I. Cell Metab. 2014;20(5):787-798. IF 17.565
94. PCSK9 inhibition for the treatment of hypercholesterolemia: promises and emerging challenges. Norata GD, Tibolla G, Catapano AL. Vascul Pharmacol. 2014;62(2):103-111. IF 3.635
95. Variants near TERT and TERC influencing telomere length are associated with high-grade glioma risk. Walsh KM, Codd V, Smirnov IV, Rice T, Decker PA, Hansen HM, Kollmeyer T, Kosel ML, Molinaro AM, McCoy LS, Bracci PM, Cabriga BS, Pekmezci M, Zheng S, Wiemels JL, Pico AR, Tihan T, Berger MS, Chang SM, Prados MD, Lachance DH, O'Neill BP, Sicotte H, Eckel Passow JE; ENGAGE Consortium Telomere Group, van der Harst P, Wiencke JK, Samani NJ, Jenkins RB, Wrensch MR. Collaborators: Codd V, Nelson CP, Albrecht E, Mangino M, Deelen J, Buxton JL, Hottenga JJ, Fischer K, Esko T, Surakka I, Broer L, Nyholt DR, Leach IM, Salo P, Hägg S, Matthews MK, Palmen J, Norata GD, O'Reilly PF, Saleheen D, Amin N, Balmforth AJ, Beekman M, de Boer RA, Böhringer S, Braund PS, Burton PR, de Craen AJ, Denniff M, Dong Y, Douroudis K, Dubinina E, Eriksson JG, Garlaschelli K, Guo D, Hartikainen AL, Henders AK, Houwing-Duistermaat JJ, Kananen L, Karssen LC, Kettunen J, Klopp N, Lagou V, van Leeuwen EM, Madden PA, Mägi R, Magnusson PK, Männistö S, McCarthy MI, Medland SE, Mihailov E, Montgomery GW, Oostra BA, Palotie A, Peters A, Pollard H, Pouta A, Prokopenko I, Ripatti S, Salomaa V, Suchiman H, Valdes AM, Verweij N, Viñuela A, Wang X, Wichmann HE, Widen E, Willemsen G, Wright MJ, Xia K, Xiao X, van Veldhuisen DJ, Catapano AL, Tobin MD, Hall AS, Blakemore AI, van Gilst WH, Zhu H, Erdmann J, Reilly MP, Kathiresan S, Schunkert H, Talmud PJ, Pedersen NL, Perola M, Ouwehand W, Kaprio J, Martin NG, van Duijn CM, Hovatta I, Gieger C, Metspalu A, Boomsma DI, Jarvelin MR, Slagboom P, Thompson JR, Spector TD, van der Harst P, Samani NJ. Nat Genet. 2014;46(7):731-735. IF 29.352
96. Inibitori di PCSK9 e dislipidemie: le evidenze cliniche. Norata GD. G Ital Cardiol 2014;15(5):301-305.
97. HDL in innate and adaptive immunity. Catapano AL, Pirillo A, Bonacina F, Norata GD. Cardiovasc Res. 2014;103(3):372-383. IF 5.940
98. Pentraxins and Atherosclerosis. Barbati E, Bottazzi B, Catapano AL, Garlanda C, Latini R, Mantovani A, Norata GD, Valentino S. 2014 Inflammation and Atherosclerosis, pp 219-237
99. PCSK9 inhibitors and dyslipidemia: The clinical evidence. Norata GD. Giornale Italiano di Cardiologia. 2014;15:301-305.
100. Telomere shortening over 6 years is associated with increased subclinical carotid vascular damage and worse cardiovascular prognosis in the general population: results from the PLIC study. Baragetti A, Palmen J, Garlaschelli K, Grigore L, Pellegatta F, Tragni, E, Catapano AL, Humphries S, Norata GD, Talmud PJ. J Intern Med. 2015;277(4):478-487. IF 7.803
101. Novel concepts in HDL pharmacology. Remaley AT, Norata GD, Catapano AL. Cardiovasc Res. 2014;103(3):423-428. IF 5.940
102. New therapeutic principles for familial hypercholesterolemia. Norata GD. Clin Biochem. 2014;47(9):756. IF 2.275
103. MiR-143/145 deficiency attenuates the progression of atherosclerosis in Ldlr-/- mice. Sala F, Aranda JF, Rotllan N, Ramírez CM, Aryal B, Elia L, Condorelli G, Catapano AL, Fernández-Hernando C, Norata GD. Thromb Haemost. 2014;112(24);796-802.
IF 4.984
104. Statins and skeletal muscles toxicity: from clinical trials to everyday practice. Norata GD, Tibolla G, Catapano AL. Pharmacol Res. 2014;88:107-113. IF 4.408
105. HDL to treat or not to treat? Pirillo A, Norata GD, Catapano AL. Curr Ath Rep. 2014;16(8):429. IF 3.417
106. Statins and periodontal inflammation: a pleiotropic effect of statins or a pleiotropic effect of LDL-cholesterol lowering? Norata GD, Catapano AL. Atherosclerosis. 2014;234(2):381-382. IF 3.994
107. Postprandial lipidemia as a cardiometabolic risk factor. Pirillo A, Norata GD, Catapano AL. Curr Med Res Opin. 2014;30(8):1489-1503. IF 2.653
108. Cardiometabolic and immune factors associated with increased common carotid artery Intima Media Thickness and cardiovascular diseases in patients with systemic lupus erythematous. Ammirati E, Bozzolo EO, Contri R, Baragetti A, Palini AG, Cianflone D, Banfi M, Uboldi P, Scotti I, Pirillo A, Grigore L, Garlaschelli K, Monaco C, Catapano AL, Sabbadini MG, Manfredi AA, Norata GD. Nutr Metab Cardiovasc Dis. 2014;24(7):751-759. IF 3.323
109. The missing link between high-density lipoprotein cholesterol and inflammatory response in cardiovascular disease. Ammirati E, Scotti I, Norata GD. J Am Coll Cardiol. 2014;63(24):2747-2748. IF 16.503
110. Pentraxin 3 (PTX3) plasma levels and carotid intima media thickness progression in the general population. Baragetti A, Knoflach M, Cuccovillo I, Grigore L, Casula M, Garlaschelli K, Mantovani A, Wick G, Kiechl S, Willeit J, Bottazzi B, Catapano AL, Norata GD. Nutr Metab Cardiovasc Dis. 2014;24(5):518-523. IF 3.323
111. Nonalcoholic fatty liver and metabolic syndrome in Italy: results from a multicentric study of the Italian Arteriosclerosis society. Soresi M et al., on behalf of the Metabolic Syndrome Study Group. Acta Diabetologica. 2013;50(2):241-249. IF 2.679
112. The thyroid receptor modulator KB3495 reduces atherosclerosis independently of total cholesterol in the circulation in ApoE deficient mice. Mork LM, Rehnmark S, Davoodpour P, Norata GD, Larsson L, Witt MR, Malm J, Parini P. PLoS One. 2013;8(12):e78534. IF 3.534
113. Targeting PCSK9 for hypercholesterolemia. Norata GD, Tibolla G, Catapano AL. Annu Rev Pharmacol Toxicol. 2014;54:273-293. IF 18.365
114. The long pentraxin PTX3: a biomarker spanning from cardiovascular to cancer. Falasca M, Bonacina F, Catapano AL, Norata GD. J Mol Biomark Diagn. 2013;4:2.
115. LOX-1, OxLDL and atherosclerosis. Pirillo A, Norata GD, Catapano AL. Mediators Inflamm. 2013;2013:152786. IF 2.417
116. New targets and developments in lipoproteins control. Norata GD. Research Reports in Clinical Cardiology 2013;4:77-84.
117. The CD1d‐Natural Killer T cell axis in atherosclerosis. Bondarenko S, Catapano AL, Norata GD. J Innate Immun. 2014;6(1):3-12. IF 4.557
118. Prevalence of classical CD14++/CD16‐ but not of intermediate CD14++/CD16+ monocytes in hypoalphalipoproteinemia. Sala F, Cutuli L, Grigore G, Pirillo A, Chiesa G, Catapano AL, Norata GD. Int J Cardiol. 2013;168(3):2886-2889.
IF 6.175
119. High density lipoproteins cholesterol levels are an independent predictor of the progression of chronic kidney disease. Baragetti A, Norata GD, Sarcina C, Rastelli F, Grigore L, Garlaschelli K, Uboldi P, Baragetti I, Pozzi C, Catapano AL. J Intern Med. 2013;274(3):252-262. IF 5.785
120. Long pentraxin 3 (PTX3): experimental and clinical relevance in cardiovascular diseases. Bonacina F, Baragetti A, Catapano AL, Norata GD. Mediators Inflamm. 2013;2013:725102. IF 2.417
121. New therapeutic principles in dyslipidaemia: focus on LDL and Lp(a) lowering drugs. Norata GD, Ballantyne CM, Catapano AL. Eur Heart J. 2013;34(24):1783-1789.
IF 14.723
122. Gene silencing approaches for the management of dyslipidemia. Norata GD, Tibolla G, Catapano AL. Trends Pharmacol Sci. 2013;34(4):198‐205. IF 9.988
123. -374 T/A RAGE polymorphism is associated with chronic kidney disease progression in subjects affected by a nephrocardiovascular disease. Baragetti I, Norata GD, Sarcina C, Baragetti A, Rastelli F, Buzzi L, Grigore L, Garlaschelli K, Pozzi C, Catapano AL. PLoS One. 2013; 8(4):e60089. IF 3.534
124. LDL Lowering Drugs: Current Perspectives. Norata GD. Cardiovascular Pharmacology 2012;2(1):1000e104.
125. European Lipoprotein Club: Report of the 35th ELC Annual Conference. Costet P, Ehrenborg E, Fisher R, Fielding B, Groen A, Kardassis D, Malle E, Mulder M, Niemeier A, Norata GD, Hansen AT, Eckardstein Av. Atherosclerosis. 2013;226(2):510‐516. IF 3.971
126. High-density lipoprotein subfractions-what the clinicians need to know. Pirillo A, Norata GD, Catapano AL. Cardiology. 2013;124:116‐125. IF 2.044
127. Class II Phosphoinositide 3‐kinases contribute to endothelial cells morphogenesis. Tibolla G, Piñeiro R, Chiozzotto D, Mavrommati I, Wheeler AP, Norata GD, Catapano AL, Maffucci T, Falasca M. PLoS One. 2013;8(1):e53808.
IF 3.534
128. The zebrafish embryo derivative affects cell viability of epidermal cells: a possible role in the treatment of psoriasis. Norata GD, Biava PM, Di Pierro F. Giornale Ital. Dermatol. Venereol. 2013, 148 (5):479–483.
129. MicroRNAs and lipoproteins: a connection beyond atherosclerosis? Norata GD, Sala F, Catapano AL, Fernández‐Hernando C. Atherosclerosis 2013;227(2):209‐215.
IF 3.971
130. Identification of seven loci affecting mean telomere length and their association with disease. Codd V, Nelson CP, Albrecht E, Mangino M, Deelen J, Buxton JL, Hottenga JJ, Fischer K, Esko T, Surakka I, Broer L, Nyholt DR, Leach IM, Salo P, Hägg S, Matthews MK, Palmen J, Norata GD, O’Reilly PF, Saleheen D, Amin N, Balmforth AJ, Beekman M, de Boer RA, Böhringer S, Braund PS, Burton PR, de Craen AJM, Denniff M, Dong Y, Douroudis K, Dubinina E, Eriksson JG, Garlaschelli K, Guo D, Hartikainen AL, Henders AK, Houwing‐ Duistermaat JJ, Kananen L, Karssen LC, Kettunen J, Klopp N, Lagou V, van Leeuwen EM, Madden P, Mägi R, Magnusson PKE, Männistö S, McCarthy MI, Medland SE, Mihailov E, Montgomery GW, Oostra BA, Palotie A, Peters A, Pollard H, Pouta A, Prokopenko I, Ripatti S, Salomaa V, Suchiman HED, Valdes AM, Verweij N, Vinuela A, Wang X, Wichmann HE, Widen E, Willemsen G, Wright MJ, Xia K, Xiao X, van Veldhuisen DJ, Catapano AL, Tobin MD, Hall AS, Blakemore AIF,van Gilst WH, Zhu H, CARDIoGRAM consortium, Erdmann J, Reilly MP, Kathiresan S, Schunkert H, Talmud PJ, Pedersen NL, Perola M,, Ouwehand W, Kaprio J, Martin NG, van Duijn CM, Hovatta I, Gieger C, Metspalu A, Boomsma D, Jarvelin MR, Slagboom PE, Thompson JR, Spector TD, van der Harst P, Samani NJ. Nat Genet. 2013;45(4):422‐427. IF 29.648
131. Pharmacogenetics in cardiovascular disorders: an update on the principal drugs. Predazzi IM, Mango R, Norata GD, Di Daniele N, Sergi D, Romeo F, Novelli G. Am J Cardiovasc Drugs. 2013;13(2):79‐85. IF 2.203
132. High density lipoproteins and atherosclerosis: emerging aspects. Sala F, Catapano AL, Norata GD. J Geriatr Cardiol. 2012;9(4):401‐407.
133. Treating high density lipoprotein cholesterol (HDL‐C): quantity versus quality. Pirillo A, Norata GD, Catapano AL. Curr Pharm Des. 2013;19(21):3841-3857. IF 3.288
134. Established and Emerging Approaches for The Management of Dyslipidaemia. Norata GD. Scientifica 2012;2012:482423.
135. HDL and adaptive immunity: a tale of lipid rafts. Norata GD, Catapano AL. Atherosclerosis 2012;225(1):34‐35. IF 3.706
136. Effects of treatment with pravastatin or ezetimibe on endothelial function in patients with moderate hypercholesterolemia. Grigore G, Raselli S, Garlaschelli K, Redaelli L, Norata GD, Pirillo A, Catapano AL. Eur J Clin Pharmacol. 2013;69(3):341‐346. IF 2.741
137. Antigen-dependent and antigen-independent pathways modulate CD4+CD28null T cells during atherosclerosis. Ammirati E, Monaco C, Norata GD. Circ Res. 2012;111(2):e48‐e49. IF 11.861
138. Carotid intima‐media thickness progression to predict cardiovascular events in the general population (the PROG‐IMT collaborative project): a meta‐analysis of individual participant data. Lorenz MW et al, on behalf of the PROG‐IMT Study Group. Lancet 2012;379(9831):2053‐2062. IF 39.060
139. A CYP26B1 polymorphism enhances retinoic acid catabolism which may aggravate atherosclerosis. Krivospitskaya O, Elmabsout AA, Sundman E, Söderström LA, Ovchinnikova O, Gidlöf AC, Scherbak N, Norata GD, Samnegård A, Törmä H, Abdel‐Halim SM, Jansson JH, Eriksson P, Sirsjö A and Olofsson PS. Mol Med. 2012;18:712‐718. IF 4.469
140. Leonurine: a new comer in the natural compounds affecting atherosclerosis. Norata GD, Catapano AL. Atherosclerosis. 2012;224(1):37‐38. IF 3.706
141. MicroRNA 143‐145 deficiency impairs vascular function. Norata GD, Pinna C, Zappella F, Elia L, Sala A, Condorelli G, Catapano AL. Int J Immunopathol Pharmacol. 2012;25(2);467‐484. IF 2.685
142. LOX-1 Inhibition in ApoE KO Mice Using a Schizophyllan-based Antisense Oligonucleotide Therapy. Amati F, Diano L, Vecchione L, Norata GD, Koyama Y, Cutuli L, Catapano AL, Romeo F, Ando H, Novelli G. Mol Ther Nucleic Acids. 2012;1:e58.
143. Effect of Tie‐2 conditional deletion of BDNF on atherosclerosis in the ApoE null mutant mouse. Norata GD, Pulakazhi Venu VK, Callegari E, Paloschi V, Catapano AL. Biochim Biophys Acta ‐ Mol Basis Dis. 2012;1822(6):927‐935. IF 4.910
144. Long pentraxin 3/tumor necrosis factor-stimulated gene-6 interaction a biological rheostat for fibroblast growth factor 2‐mediated angiogenesis. Leali D, Inforzato A, Ronca R, Belleri M, Coltrini D, Bianchi R, Di Salle E, Sironi M, Norata GD, Bottazzi B, Garlanda C, Day AJ, Presta M. Arterioscler Thromb Vasc Biol. 2012;32(3):696‐670.
IF 6.338
145. Effector memory T cells are associated with atherosclerosis in humans and animal models.Ammirati E, Cianflone D, Vecchio V, Banfi M, Vermi AC, De Metrio M, Grigore L, Pellegatta F, Pirillo A, Garlaschelli K, Manfredi AA, Catapano AL, Maseri A, Palini A, Norata GD. J Am Heart Assoc. 2012;1(1):27‐41.
146. Association between OLR1 K167N SNP and intima media thickness of the common carotid artery in the general population. Predazzi IM, Norata GD, Vecchione L, Garlaschelli K, Amati F, Grigore G, Cutuli L, Pirillo A, Romeo F, Novelli G, Catapano AL. PLoS One. 2012;7(2):e31086. IF 3.730
147. Association between the adherence to AHA Step 1 nutrition criteria and the cardiometabolic outcome in the general population a two year follow‐up study. Redaelli L, Garlaschelli K, Grigore G, Norata GD, Catapano AL. Food and Nutrition Sciences. 2012;3:274‐280.
148. Proprotein convertase subtilisin/kexin type 9 (PCSK9): from structure‐function relation to therapeutic inhibition. Tibolla G, Norata GD, Artali R, Meneghetti F, Catapano AL. Nutr Metab Cardiovasc Dis. 2011;21(11):835‐843. IF 3.731
149. The androgen derivative 5α-androstane-3β,17β-diol inhibits tumor necrosis factor α and lipopolysaccharide induced inflammatory response in human endothelial cells and in mice aorta. Norata GD, Cattaneo P, Poletti A, Catapano AL. Atherosclerosis. 2010; 212:100‐6. IF 4.086
150. HDLs, immunity, and atherosclerosis. Norata GD, Pirillo A, Catapano AL. Curr Opin Lipidol. 2011;22(5):410‐416. IF 6.086
151. Emerging role of high density lipoproteins as a player in the immune system. Norata GD, Pirillo A, Ammirati E, Catapano AL. Atherosclerosis 2012;220(1):11‐21.
IF 3.794
152. Therapy and clinical trials: aggressive statin therapy vs combined and emerging approaches. Catapano AL, Norata GD, Pirillo A. Curr Opin Lipidol. 2011;22(4):324‐325. IF 6.086
153. Immunità ed aterosclerosi: aspetti emergenti. Norata GD, Ammirati E, Cutuli L, Catapano AL. Il Giornale dell’Aterosclerosi. 2011;1:13‐24.
154. Novel biotinylated bile acid amphiphiles: micellar aggregates formation and interaction with hepatocytes. Rizzi L, Braschi M, Colombo M, Vaiana N, Tibolla G, Norata GD, Catapano AL, Romeo S, Propseri D. Org Biomol Chem. 2011;9(8):2899‐2905. IF 3.696
155. Circulating CD4+CD25hiCD127lo regulatory T‐cell levels do not reflect the extent or severity of carotid and coronary atherosclerosis. Ammirati E, Cianflone D, Banfi M, Vecchio V, Palini A, De Metrio M, Marenzi G, Panciroli C, Tumminello G, Anzuini A, Palloshi A, Grigore L, Garlaschelli K, Tramontana S, Tavano D, Airoldi F, Manfredi AA, Catapano AL, Norata GD. Arterioscler Thromb Vasc Biol. 2010; 30(9):1832‐1841.
IF 7.215
156. The long pentraxin PTX3: a modulator of the immuno‐inflammatory response in atherosclerosis and cardiovascular diseases. Norata GD, Garlanda C, Catapano AL. Trends Cardiovasc Med. 2010;20(2):35‐40. IF 3.250
157. Individual progression of carotid intima media thickness as a surrogate for vascular risk (PROG‐IMT) ‐ rationale and design of a meta‐analysis project. Lorenz MW, Bickel H, Bots ML, Breteler MMB, Catapano AL, Desvarieux M, Hedblad B, Iglseder B, Johnsen SH, Juraska M, Kiech S, Mathiesen EB, Norata GD, Grigore L, Polak J, Poppert H, Rosvall M, Rundek T, Sacco RL, Sander D, Sitzer M, Steinmetz H, Stensland E, Willeit J, Witteman J, Yanez D, Thompson SG, Prof. The PROG‐IMT Study Group. Am Heart J. 2010;159(5):730‐736. IF 5.052
158. Lecithin:Cholesterol Acyltransferase and vascular disease. Norata GD, Catapano AL. Clinical Lipidology. 2010;5:13-15.
159. Increased atherosclerosis and vascular inflammation in APP transgenic mice with Apolipoprotein E deficiency. Tibolla G, Norata GD, Meda C, Arnaboldi L, Uboldi P, Piazza F, Ferrarese C, Corsini A, Maggi A, Vegeto E, Catapano AL. Atherosclerosis. 2010;210(1):78‐87. IF 4.086
160. Effects of PCSK9 variants on common carotid artery intima media thickness and relation to ApoE alleles. Norata GD, Garlaschelli K, Grigore L, Raselli S, Tramontana S, Meneghetti F, Artali R, Noto D, Cefalù AD, Buccianti G, Averna M, Catapano AL. Atherosclerosis. 2010;208(1):177‐182. IF 4.086
161. Cholesterol absorption inhibitors. Norata GD, Catapano AL. 2009 Clinical Lipidology: a Companion to Braunwald's Heart Disease. Pp. 288-297
162. Deficiency of the long pentraxin PTX3 promotes vascular inflammation and atherosclerosis. Norata GD, Marchesi P, Pulakazhi Venu VK, Pasqualini F, Anselmo A, Moalli F, Pizzitola I, Garlanda C, Mantovani A, Catapano AL. Circulation. 2009;120(8):699‐708. IF 14.816
163. Small dense LDL and VLDL predict common carotid artery IMT and elicit an inflammatory response in peripheral blood mononuclear and endothelial cells. Norata GD, Raselli S, Grigore L, Garlaschelli K, Vianello D, Bertocco S, Zambon A, CatapanoAL. Atherosclerosis. 2009;206(2):556‐562. IF 4.522
164. Plasma adiponectin levels in chronic kidney disease patients: relation with molecular inflammatory profile and metabolic status. Norata GD, Baragetti I, Raselli S, Stucchi A, Garlaschelli K, Vettoretti S, Piloni G, Buccianti G, Catapano AL. Nutr Metab Cardiovasc Dis. 2010;20(1):56‐63. IF 3.438
165. La microalbuminuira è un marcatore indipendente di danno cardiovascolare subclinico in soggetti affetti da disfunzione renale cronica. Baragetti I, Buzzi L, Stucchi A, Sarcina C, Buccianti G, Catapano AL, Norata GD. Il Bassini; volume XXVIII Gennaio‐Giugno 2008;26‐31.
166. Circulating soluble receptor for advance glycation end products is inversely associated with body mass index and waist/hip ratio in the general population. Norata GD, Garlaschelli K, Grigore L, Tibolla G, Raselli S, Redaelli L, Buccianti G, Catapano AL. Nutr Metab Cardiovasc Dis. 2009;19(2):129‐134. IF 3.517
167. Il tessuto adiposo come possibile bersaglio di danno cardiovascolare in corso di disfunzione renale. Baragetti I, Norata GD, Raselli S, Stucchi A, Terranno V, Catapano AL, Buccianti G. Il Bassini; volume XXVII Luglio‐Dicembre 2007;9‐13.
168. Long pentraxin 3, a key component of innate immunity, is modulated by high density lipoproteins in endothelial cells. Norata GD, Marchesi P, Pirillo A, Uboldi P, Chiesa G, Maina V, Garlanda C, Mantovani A, Catapano AL. Arterioscl Thromb Vasc Biol. 2008;28(5):925‐931. IF 6.858
169. The relationship between leptin: Adiponectin ratio and carotid intima‐media thickness in asymptomatic females ‐ Response to letter by Kotani et al. Norata GD, Magni P, Catapano AL. Stroke 2008;39:e34. IF 6.499
170. Combination therapy in cholesterol reduction: focus on ezetimibe and statins. Grigore L, Norata GD, Catapano AL. Vasc Health Risk Manag. 2008;4(2):1‐12.
171. Inhibition of synthesis and absorption of cholesterol: a new option in managing hypercholesterolemia. Grigore L, Norata GD, Catapano AL. International Congress Series 2007;1303:121‐128.
172. Leptin:adiponectin ratio is an independent predictor of intima‐media thickness of the common carotid artery. Norata GD, Raselli S, Grigore L, Garlaschelli K, Dozio E, Magni P, Catapano AL. Stroke 2007;38(10):2844‐2846. IF 6.296
173. ApoE gene delivery inhibits severe hypercholesterolemia in newborn ApoE‐KO mice. Signori E, Rinaldi M, Fioretti D, Iurescia S, Seripa D, Perrone G, Norata GD, Catapano AL, Fazio VM. Biochem Biophys Res Comm. 2007;361(2):543‐548.
IF 2.749
174. Associazione tra polimorfismo –374T/A del RAGE e gravità dela disfunzione renale in pazienti affetti da insufficienza renale cronica (IRC). Stucchi A, Terranno V, Baragetti I, Tibolla G, Vettoretti S, Raselli S, Norata GD, Buzzi L, Catapano AL, Buccianti G. Il Bassini 2007; XXVII;12‐17.
175. Triglyceride‐rich lipoproteins from normotriglyceridemic subjects and hyperlipidemic patients differently affect endothelial cell activation and gene expression patterns. Norata GD, Catapano AL. Circ Res. 2007;100(7):e81. IF 9.721
176. Triglyceride‐rich lipoproteins and endothelial dysfunction: molecular mechanisms and gene expression studies. Norata GD, Catapano AL. Future Lipidology 2007;2;119‐122.
177. Effect of the -420C/G variant of the resistin gene promoter on metabolic syndrome, obesity, myocardial infarction and renal dysfunction. Norata GD, Ongari M, Garlaschelli K, Tibolla G, Grigore L, Raselli S, Vettoretti S, Baragetti I, Noto D, Cefalù AB, Buccianti G, Averna M , AL Catapano. J Intern Med. 2007;262(1):104‐112.
IF 4.901
178. Plasma resistin levels correlate with determinants metabolic syndrome. Norata GD, Ongari M, Garlaschelli K, Raselli S, Grigore L, Catapano AL. Eur J Endocrinol. 2007;156(2):279‐284. IF 3.239
179. Post‐prandial endothelial dysfunction in hypertriglyceridemic subjects: molecular mechanisms and gene expression studies. Norata GD, Grigore L, Raselli S, Redaelli L, Hamsten A, Maggi F, Eriksson P, Catapano AL. Atherosclerosis. 2007;193(2):321‐327.
IF 4.287
180. Anti‐inflammatory and anti‐atherogenic effects of cathechin, caffeic acid and trans-resveratrol in apolipoprotein E deficient mice. Norata GD, Marchesi P, Passamonti S, Pirillo A, Violi F, Catapano AL. Atherosclerosis. 2007;191(2):265‐271. IF 4.287
181. Effects of fractalkine receptor variants on common carotid artery intima‐media thickness. Norata GD, Garlaschelli K, Ongari M, Raselli S, Grigore L, Catapano AL. Stroke. 2006;37(6):1558‐1561. IF 5.391
182. Oxidized‐HDL3 modulates the expression of Cox‐2 in human endothelial cells. Callegari E, Norata GD, Inoue H, Catapano AL. Int J Mol Med. 2006;18(1):209‐13.
IF 1.867
183. HDL and endothelial function: from molecular mechanisms to clinical observations. Norata GD, Raselli S, Catapano AL. Future Lipidology 2006;1:343‐355.
184. Triglyceride‐rich lipoproteins from hypertriglyceridemic subjects induce a proinflammatory response in the endothelium: molecular mechanisms and gene expression studies. Norata GD, Grigore L, Raselli S, Seccomandi P, Hamsten A, Maggi FM, Eriksson P, Catapano AL. J Mol Cell Cardiol. 2006;40(4):484‐494. IF 4.859
185. In vitro isolation of circulating endothelial progenitor cells is related to high density lipoprotein plasma levels. Pellegatta F, Bragheri M, Grigore L, Raselli S, Maggi FM, Brambilla C, Reduzzi A, Pirillo A, Norata GD, Catapano AL. Intern J Mol Med. 2006;17(2):203‐208. IF 1.854
186. Modified HDL: biological and physiopathological consequences. Norata GD, Pirillo A, Catapano AL. Nutr Metab Cardiovasc Dis. 2006;16(5):371‐386. IF 1.867
187. Dihydrotestosterone decreases tumor necrosis factor a and lipopolysaccharide induced endothelial inflammatory response. Norata GD, Tibolla G, Seccomandi PM, Poletti A, Catapano AL. J Clin Endocrinol Metab. 2006;91(2):546‐554. IF 5.799
188. Effect of the Toll-like receptor 4 (TLR-4) variants on intima-media thickness and monocyte-derived macrophage response to LPS. Norata GD, Garlaschelli K, Ongari M, Raselli S, Grigore L, Benvenuto F, Maggi FM, Catapano AL. J Intern Med. 2005;258(1):1‐7. IF 4.040
189. Liver X receptor and retinoic X receptor agonist modulate the expression of genes involved in lipid metabolism in human endothelial cells. Norata GD, Ongari M, Uboldi P, Pellegatta F, Catapano AL. Intern J Mol Med. 2005;16(4):717‐723. IF 2.090
190. Molecular mechanisms responsible for the anti‐inflammatory and protective effect of HDL on the endothelium. Norata GD, Catapano AL. Vasc Health Risk Manag. 2005;1(2):119‐129.
191. High‐density lipoproteins induce transforming growth factor beta 2 expression in human endothelial cells. Norata GD, Callegari E, Marchesi M, Chiesa G, Eriksson P, Catapano AL. Circulation. 2005;111(21):2805‐2811. IF 11.632
192. Oxidized‐HDL3 induces the expression of PAI‐1 in human endothelial cells. Role of p38 MAPK activation and mRNA stabilization. Norata GD, Banfi C, Pirillo A, Tremoli E, Hamsten A, Catapano AL, Eriksson P. Br J Haematol. 2004;127(1):97‐104.
IF 3.195
193. Matrix metalloproteinase‐26 (matrylisin‐2) expression in high in endometrial hyperplasia and decreases with loss of histologic differentiation in endometrial cancer. Pilka R, Norata GD, Domanski H, Hansson S, Eriksson P, Casslen B. Gynecol Oncol. 2004; 94(3):661‐670. IF 2.083
194. Native LDL and Ox‐LDL modulate cyclooxygenase‐2 expression in HUVECs through a p38‐MAPK NF‐kB, CRE dependent pathways and ffects on PGE2 synthesis. Norata GD, Pirillo A, Pellegatta F, Inoue H, Catapano AL. Int J Mol Med. 2004;14(3):353‐359. IF 3.190
195. Tryglicerides rich lipoproteins and atherosclerosis: in vitro and in vivo studies. Norata GD, Raselli S, Grigore L, Maggi FM, Catapano AL. International Congress Series, 2004;1262:507‐510.
196. HDL3 induce cyclooxygenase‐2 expression and prostacyclin release in human endothelial cells via a p38 MAPK/CRE dependent pathway: Effects on COX‐2/PGI‐S coupling. Norata GD, Callegari E, Inoue H, Catapano AL. Arterioscler Thromb Vasc Biol. 2004;24(5):871‐877. IF 7.432
197. High density lipoprotein subfracion 3 decreases ADAMTs-1 expression induced by LPS and TNFα in human endothelial cells. Norata GD, Bjork H, Hamsten A, Catapano AL, Eriksson P. Matrix Biol. 2004;22(7):557‐560. IF 4.104
198. Lipid lowering activity of drugs affecting cholesterol absorption. Norata GD, Catapano AL. Nutr Metab Cardiovasc Dis. 2004;14(1):42‐51. IF 1.253
199. Gene expression and intracellular pathways involved in endothelial dysfunction induced by VLDL and oxidised VLDL. Norata GD, Pirillo A, Callegari E, Hamsten A, Catapano AL, Eriksson P. Cardiovasc Res. 2003;59(1):169‐180. IF 5.164
200. Effects of HDL3 on the expression of matrix-degrading proteases in human endothelial cells. Norata GD, Pellegatta F, Hamsten A, Catapano AL, Eriksson P. Int J Mol Med. 2003;12(1):73‐78. IF 1.940
201. Statins and oxidative stress during atherogenesis. Norata GD, Pirillo A , Catapano AL. Eur J Prev Cardiol. 2003;10(3):181‐9. IF 1.990
202. PPARs e Patologie Cardiovascolari. Norata GD, Pellegatta F, Catapano AL. Ital Heart J Suppl. 2003;4:8‐18.
203. Peroxisome proliferation activated receptors and cardiovascular disease. Norata GD, Pellagatta F, Catapano AL. Ital Heart J Suppl. 2003;4(1):8-18.
204. Apoptosis and proliferation of endothelial cells in early atherosclerotic lesions: a possible role for oxidized LDL. Norata GD, Tonti L, Roma P, Catapano AL. Nutr Metab Cardiovasc Dis. 2002;12(5):297‐305. IF 1.679
205. Lipoproteine ossidate e endotelio. Pirillo A, Norata GD, Catapano AL. Giornale dellʹAterosclerosi. 2002;27:53‐57.
206. Overexpression of Inducible Heat Shock Protein 70in COS-1 cells fails to protect from cytotoxicity of oxidized LDLs. Pirillo A, Norata GD, Zanelli T, Catapano AL. Arterioscler Thromb Vasc Biol. 2001;21(3):348‐354. IF 5.816
207. Oxidized lipoproteins and endothelium. Pirillo A, Zhu W, Norata GD, Zanelli T, Barberi L, Roma P, Catapano AL. Clin Chem Lab Med. 2000;38(2):155‐160. IF 1.744
Riconoscimenti e premi
2010: Premio giovani ricercatori European Atherosclerosis Society
2010: Premio giovani ricercatori MAJORS: the Metabolic Atherosclerotic Joint Regional
Symposium, Dublino
2009: Premio SISA per giovani ricercatori
2006: Premio giovani ricercatori SISA
2005: Premio giovani ricercatori consegnato da European Lipoprotein Club
2004: Premio giovani ricercatori SISA e SISA Lombardia
2003: Premio giovani ricercatori SISA 2002: Premio giovani ricercatori SISA 2001: Grant
del MIUR (Ministero Istruzione Università e Ricerca) per il progetto: "In vitro studies on the
inflammatory response induced by post-prandial lipoproteins in endothelial cells"
2000: Premio SISA
2000: Finalista per il Young Award Investigator al XII International Symposium on Atherosclerosis, Stoccolma
1999: Premio giovani ricervatori SISA.
1997: Premio SISA (Società Italiana Studio Aterosclerosi)
1997: Finalista per il Young Award Investigator all’XI International Symposium on Atherosclerosis, Parigi
Dati personali Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 (Codice in materia di protezione dei dati personali) e sue successive modifiche e integrazioni, nonché del Regolamento UE 679/2016 (Regolamento Generale sulla Protezione dei dati o, più brevemente, RGPD).
Autorizzo, ai sensi del D. Lgs 14/03/2013 n.33 (Riordino della disciplina riguardante gli obblighi di pubblicita', trasparenza e diffusione di informazioni da parte delle pubbliche amministrazioni), la pubblicazione di questo curriculum sul sito web dell’Università degli Studi di Milano nella sezione “Amministrazione trasparente”, “Consulenti e Collaboratori”.